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ABSTRACT OF THE DISSERTATION 
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Professor Daniel C. Link, Chairperson 
 
Recent studies have demonstrated the efficacy of hematopoietic cell-based 
therapies in promoting therapeutic angiogenesis for a wide variety of vascular 
syndromes, however the cell populations responsible and the mechanisms involved 
are poorly understood.  Using a mouse model of hindlimb ischemia, we previously 
showed that an adoptive transfer of donor monocytes significantly enhanced 
revascularization.  Monocytes are a widely heterogeneous cell population and 
differences in the ability of various monocyte subsets to mediate revascularization 
have not been previously investigated.  Using the hindlimb ischemia model we 
demonstrate that an adoptive transfer of inflammatory (CX3CR loGr-1+), but not 
resident (CX3CR1hiGr-1-) monocytes, significantly enhances revascularization post-
ischemia.  Additionally, we show that the inflammatory subset of monocytes is 
selectively recruited from the bone marrow to the blood and that these cells 
accumulate at the ischemic lesion.  These findings demonstrate that the adoptive 
transfer of only a small proportion of monocytes from a non-ischemic donor 
significantly enhances revascularization despite the presence of a far greater 
  
iii 
proportion of endogenous (ischemia-conditioned) monocytes.  Herein, we provide 
data suggesting that upon induction of distant ischemia, systemic signals are 
generated which reduce the angiogenic capacity of bone marrow resident monocytes.  
We provide evidence that granulocyte-colony stimulating factor (G-CSF) and 
interleukin-6 (IL-6) provide these “conditioning” signals.  Systemic levels of G-CSF 
and IL-6 are significantly increased following induction of hindlimb ischemia, and 
accordingly, bone marrow resident monocytes from ischemic mice exhibited 
increased STAT3 phosphorylation and STAT3 target gene expression.  Finally, G-
CSF receptor-/- and IL-6-/- mice were resistant to the deleterious effects of ischemic 
conditioning on monocyte angiogenic potential.  The mechanism by which this 
ischemia-driven signals limit the angiogenic potential of monocytes was examined 
using RNA expression profiling which suggested that ischemia-conditioned 
monocytes in the bone marrow are polarized towards expression of M2-associated 
genes.  Consistent with this observation, M2-skewed monocytes from SHIP-/- mice 
also had impaired angiogenic capacity.  Lastly we demonstrate that the efficacy of an 
adoptive transfer of non-ischemic donor monocytes may be due, at least in part, to 
increased expression of the fractalkine receptor CX3CR1 as well as to increases in 
local concentrations of the angiogenic factors MCP-1, VEGF, MMP-9 and ApoA1.   
 
 
 
 
 
  
iv
ACKNOWLEDGEMENTS 
 
 
I would like to thank the members of my thesis committee and in particular my thesis 
mentor Dan Link for helpful advice and ideas. 
 
I would like to acknowledge Ben Capoccia for laying the foundation for these studies 
in his own thesis work and for being such a helpful and willing collaborator.   
 
Lastly, I would like to thank Jill Woloszynek, Matthew Christopher, Amy Rawls, 
Ivana Rosova, and Morgan Mclemore for their helpful discussions and extensive 
expertise which played such an important role in my training. 
 
 
 
 
 
 
 
 
 
 
 
  
v
TABLE OF CONTENTS 
Abstract of Dissertation         ii 
Acknowledgements          iv 
List of Figures and Tables        ix 
 
Chapter 1 Introduction 
 1.1  Angiogenesis        2 
  1.1.1  Types of angiogenesis      2 
  1.1.2. Hindlimb ischemia model of angiogenesis   3 
1.2  Monocyte regulation of angiogenesis     5 
  1.2.1. In vitro and animal model findings    5 
  1.2.2.  Clinical trials utilizing BM-MNCs    7 
1.3  Monocyte biology       9 
  1.3.1   Development and functions     9 
  1.3.2.  M1/M2 polarization      10 
  1.3.3.  CX3CR1 monocyte subsets     12 
  1.3.4.  Tie2 monocyte subsets     14 
1.4  CX3CR1/fractalkine receptor      16 
1.5  Apolipoprotein A1                  19
 1.6  Summary         21 
1.8  References        22 
  
 
  
vi
Chapter 2   The inflammatory subset of monocytes potently stimulates post-  
ischemic angiogenesis 
2.1  Abstract         31 
2.2 Introduction        31 
2.3  Materials and Methods       35 
2.4  Results 
  2.4.1  Monocytes are recruited to ischemic tissue post-HLI  37 
2.4.2  An adoptive transfer of the inflammatory, but not resident,    38 
subset of monocytes significantly improves revascularization  
post-HLI 
2.4.3  The inflammatory subset of monocytes is selectively   39 
mobilized from the bone marrow into the blood post-HLI 
2.4.4  Monocytes of the inflammatory subset accumulate at            39 
the ischemic lesion post-HLI 
2.4.5  Bone marrow resident monocytes decrease expression of      40  
CX3CR1 upon induction of ischemia and CX3CR1-/- monocytes 
exhibit a reduced ability to improve angiogenesis.    
2.4.6  Local production of VEGF, MCP-1, MMP-9,   41 
and apolipoprotein A1 is increased post-adoptive transfer.   
2.4.7.  An adoptive transfer of apolipoprotein A1-deficient  41 
 monocytes does not improve revascularization post-HLI.   
 2.5  Discussion        42 
2.6  Figures and Figure Legends      47 
  
vii
 
2.7  References        58 
 
Chapter 3 Systemic Signals Generated by IL-6 and G-CSF Influence the 
Angiogenic Capacity of Bone Marrow Resident Monocytes 
3.1  Abstract         63 
3.2  Introduction         64 
3.3  Materials and Methods       66 
3.4  Results 
3.4.1  The addition of a small proportion of macrophages  70 
obtained from a non-ischemic donor significantly improves 
revascularization post-HLI 
3.4.2  An adoptive transfer of BM-MNCs obtained from an  71 
ischemic donor does not improve revascularization post-HLI 
3.4.3  Ischemia-conditioned monocytes are not competent to  72 
mediate revascularization 
3.4.4.  Adoptively transferred ischemia-conditioned   73 
monocytes are competent to home to ischemic tissue 
3.4.5  Increased STAT3 phosphorylation is observed in   73 
ischemia-conditioned bone marrow monocytes 
3.4.6  IL-6 and G-CSF are produced upon induction of   74 
ischemia and loss of either of these signals is sufficient to  
restore the ability of ischemic adoptively transferred  
  
viii 
monocytes to promote angiogenesis 
3.4.7  Ischemia-conditioned bone marrow monocytes   75 
demonstrate a shift toward expression of M2 genes and  
M2 skewed monocytes do not accelerate revascularization 
3.5  Discussion        76 
3.6  Figures and Figure Legends      80 
3.7  References        91 
 
Chapter 4 Summary and Future Directions 
4.1  Summary         96 
4.2  Application to other ischemic models     97 
4.3  Role of type I interferon                  99
 4.4  Clinical trial using mobilizing agents to recruit monocytes  100 
4.5 References        102 
 
 
 
 
 
 
 
 
 
  
ix
LIST OF FIGURES AND TABLES 
 
Chapter 1:  Introduction 
Figure 1  Schematic of femoral artery excision and laser Doppler imaging   4 
Table 1   Clinical trials utilizing BM-MNC transplantation     8 
Table 2  CX3CR1/Gr-1 monocyte subsets in mice               14 
Table 3  CD14/CD16 monocytes subsets in humans    14 
 
Chapter 2:  The Inflammatory Subset of Monocytes Potently Stimulates Post-
Ischemic Angiogenesis  
Figure 2.1 Adoptively transferred donor monocytes home to the 51 
site of ischemia and a concomitant recruitment of  
additional endogenous monocytes is observed.   
Figure 2.2 An adoptive transfer of the inflammatory, but not   52 
resident, subset of monocytes significantly improves 
revascularization post-HLI.   
Figure 2.3 The inflammatory subset of monocytes is selectively  53 
mobilized from the bone marrow into the blood  
post-HLI 
Figure 2.4 Monocytes of the inflammatory subset accumulate   54 
at the ischemic lesion post-HLI 
Figure 2.5 Expression of CX3CR1 is decreased upon induction  55 
  
x
of ischemia and CX3CR1-/- monocytes demonstrate  
a reduced capacity to stimulate angiogenesis. 
Figure 2.6 Local production of VEGF, MCP-1, MMP-9,   56 
and apolipoprotein A1 is increased post-adoptive  
transfer 
Figure 2.7 An adoptive transfer of apolipoprotein A1-deficient  57 
monocytes does not improve revascularization  
post-HLI 
 
Chapter 3:  Systemic Signals Generated by IL-6 and G-CSF Influence the 
Angiogenic Capacity of Bone Marrow Resident Monocytes 
Figure 3.1 The addition of a small proportion of macrophages   80 
obtained from a non-ischemic donor significantly  
improves revascularization post-hindlimb ischemia.   
Figure 3.2 An adoptive transfer of BM-MNCs obtained from   81 
an ischemic donor does not improve revascularization  
post-HLI.   
Figure 3.3 Ischemia-conditioned monocytes are not competent   82 
to mediate revascularization.   
Figure 3.4 Adoptively transferred ischemia-conditioned   83 
monocytes are competent to home to ischemic tissue.   
Figure 3.5 Increased STAT3 phosphorylation is observed in   84 
ischemia-conditioned bone marrow monocytes.   
  
xi
Figure 3.6 IL-6 and G-CSF are produced upon induction of   85 
ischemia and loss of either of these signals is  
sufficient to restore the ability of ischemic adoptively 
transferred monocytes to promote angiogenesis.   
Figure 3.7 Differential M1/M2 gene expression post-ischemic               86 
conditioning, and reduced revascularization  
capacity of SHIP-/- M2-skewed monocytes.  
Table 3.1    Genes upregulated in ischemia-conditioned bone   87 
Marrow monocytes 
Table 3.2 Genes downregulated in ischemia-conditioned   88 
bone marrow monocytes 
 Table 3.3 M1-associated genes      89 
Table 3.4 M2-associated genes      90 
 
 
 
 
 
 
 
 
 
 
  
1
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 1 
 
 
Introduction 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
2
1.1  Angiogenesis 
1.1.1  Types of neovascularization   
Neovascularization is a critical biological process in a variety of 
developmental, repair, and pathological settings.  The general term neovascularization 
describes three distinct processes that result in the formation of blood vessels:  
vasculogenesis, arteriogenesis, and angiogenesis.  Vascuolgenesis refers to the de 
novo formation of vascular structures from mesenchymal angioblasts (Risau, 1995).  
Postnatally, some vasculogenesis mediated by endothelial progenitor cells may occur, 
however the contribution of this process to adult neovascularization is controversial 
(Asahara, 1999; Simons, 2003).  In adults, blood vessel formation occurs by two 
distinct mechanisms referred to as angiogenesis and arteriogenesis.  Arteriogenesis 
refers to the enlargement of pre-existing vessels to form arteries which have 3 distinct 
wall layers as well as vasomotor activity (Helisch, 2003).  In contrast, during 
angiogenesis new capillary networks are formed due to the recruitment of local 
endothelial cells from nearby vessels which assemble into vascular structures in a 
process referred to as tube formation (Folkman, 2005).  The two processes by which 
angiogenesis can occur are referred to as “sprouting” in which a new branch is 
formed from an existing vessel, or “intussusception” which refers to the splitting of a 
pre-existing capillary.  Each of these processes results in the formation of a thin-
walled endothelial cell-lined capillary.  The studies outlined below will focus 
exclusively on post-ischemic neovascularization.  Angiogenesis is a major contributor 
to post-ischemic neovascularization as only this process, and not arteriogenesis, is 
induced in response to hypoxia-inducible factor-1α (HIF-1α) expression which is 
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induced under conditions of ischemia/hypoxia (Madeddu, 2005; Schaper, 2003).  
However, both angiogenic and arteriogenic mechanisms are triggered by shear stress 
which is generated in ischemic tissues and thus both processes are involved in 
recovery from ischemic insult.             
 
1.1.2  Hindlimb ischemia model of angiogenesis 
In order to study post-ischemic neovascularization, we will utilize a mouse 
model first described by Couffinhal, et al. for femoral artery excision (FAE) which 
results in hindlimb ischemia (HLI) (1998).  In this model, the right hindlimb is 
dissected to allow visualization of the femoral artery.  The obturator nerve which runs 
directly parallel and in close proximity to the femoral artery is dissected away from 
the artery taking care that it remains intact.  The femoral artery and all of its side 
branches, as well as the proximal saphenous artery are then ligated and the portions of 
the vessels located between these points of ligation are excised.  Laser Doppler 
imaging is used to monitor the disruption and subsequent restoration of blood flow to 
the ischemic hindlimb.  Imaging software assigns a “flux value” describing the 
surface blood flow observed.  As ischemia is induced in a unilateral fashion, the 
amount of blood flow present in the non-ischemic leg is used as an internal control to 
minimize variations among individual mice.  Blood flow recovery is thus reported as 
the ratio of the flux value observed in ischemic hindlimb divided by the flux value 
observed in the non-ischemic hindlimb abbreviated as (ischemic:non-ischemic).  Prior 
to femoral artery excision, the flux values obtained for the right and left hindlimbs are 
nearly identical, resulting in a flux ratio of approximately 1.0.  In contrast, post-HLI, 
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blood flow to limb undergoing femoral artery excision is nearly absent, resulting in a 
flux ratio of approximately 0.1.  Mice are monitored over a 14-day time course to 
assess revascularization.  Of note, in our studies laser Doppler quantitation is 
performed only on the foot region of the mouse, excluding the adductor and calf 
muscle regions.  Histological analyses suggest that angiogenesis is the major repair 
mechanism present in the ischemic calf muscle and foot while arteriogenesis is 
responsible for repair of the ischemic adductor muscle (Wahlberg, 2006; Shireman, 
2007).  Thus angiogenesis, and not arteriogenesis, is the major neovascularization 
process reflected in this model. 
 
 
Figure 1.1 
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1.2  Monocyte regulation of angiogenesis 
1.2.1  In vitro and animal model findings 
Monocytes are known to play a critical role in promoting angiogenesis in a 
wide variety of settings including wound repair, rheumatoid arthritis, tumor 
development, and ischemic injury (Sunderkotter, 1994).  Monocytes play a variety of 
distinct roles in regulating the angiogenic process.  First, they exhibit proteolytic and 
phagocytic activity which allows for the degradation and removal of damaged tissue, 
thus generating an appropriate scaffolding upon which new blood vessels can be 
formed.  Secondly, macrophages generate a wide range of cytokines which recruit 
and/or activate additional inflammatory cells (MCP-1, IL-8) or endothelial cells 
(VEGF).  Lastly, several studies have reported that monocytes may, in fact, be able to 
incorporate into developing vasculature.  Recent evidence however, has demonstrated 
that CD45+ hematopoietic cells do not incorporate into developing endothelium 
(Capoccia, 2006).  Monocytes are recruited to hypoxic areas and produce angiogenic 
factors which stimulate endothelial cells located in nearby areas to migrate, 
proliferate, and differentiate into new vessels (Lewis, 2005).  In response to hypoxia, 
macrophages produce VEGF, a mitogen specific to endothelial cells which is potently 
angiogenic (Leung, 1989).  Additionally, macrophages have been shown to express 
the inflammatory mediators IL-1, TNF, IL-6, and arginase-1 (Arg1) in response to 
hypoxia (Bosco, 2008).   
In addition to the phagocytic, proteolytic, and proinflammatory properties 
described above, monocyte/macrophages have also been ascribed two unique 
functions outlined in recent studies.  First, although macrophages are largely thought 
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to be non-dividing, several studies have indicated a limited degree of proliferation in 
response to co-culture with endothelial cells and M-CSF in vitro (Cheung, 1992; 
Munn, 1993; Antonov, 1997).  However, the contribution of local proliferation of 
macrophages under inflammatory conditions in vivo is unclear.  Second, an additional 
study using a mouse transgenic model of ischemic cardiomyopathy has indicated that 
macrophages can drill endothelial cell-free“tunnels” using macrophage 
metalloelastase which penetrate the ischemic myocardium (Moldovan, 2000).  
Whether of not these tunnels are subsequently colonized by endothelial cells to form 
capillaries is unknown.   
In light of the well-established important roles played by monocytes in 
mediating angiogenesis, several groups have explored the possibility that a local 
injection or intravenous adoptive transfer of monocytes may serve as an efficacious 
treatment for a variety of angiogenic disorders.  Recent studies by Capoccia et al. 
have demonstrated that an adoptive transfer of bone marrow mononuclear cells, and 
in particular the monocyte fraction contained within this population, significantly 
enhanced blood flow recovery post-hindlimb ischemia in mice (2006, 2008).  These 
findings were corroborated by (Zhang, 2008) and extended to myocardial infarction 
models (Burchfield, 2008; Ziebart, 2008).  Studies such as these provided the 
rationale for the clinical trials described below. 
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1.2.2  Clinical trials utilizing monocytes 
Promising reports using mouse modeling have prompted a variety of clinical 
trials in which bone marrow-derived mononuclear cells are used as a treatment for 
ischemic disorders including myocardial infarction and critical limb ischemia.  
Critical limb ischemia (CLI) is a severe manifestation of peripheral arterial disease 
(PAD).  The estimated annual incidence of CLI ranges between 500 and 1,000 new 
cases per 1 million, and occurs most frequently in patients with diabetes or severe 
atherosclerosis (Minar, 2009).  The primary goals of treatment in patients with CLI 
are to relieve ischemic pain and to treat ischemic ulcers, and in the most severe cases 
to prevent loss of the ischemic limb.  In an effort to treat CLI, the growth factor 
proteins VEGF and bFGF have been administered locally, however results to this 
type of treatment have been mixed (Al Sabti, 2007).  These mixed results are not 
entirely surprising as these proteins have a short serum half-life and a sole factor is 
unlikely to recapitulate all the signals necessary to induce angiogenesis.   
As a means of circumventing the limitations of single protein therapies, recent 
studies have focused on cell-based approaches to therapeutic angiogenesis.  Studies in 
animal models demonstrating the efficacy of hematopoietic cells, in promoting 
angiogenesis led to the rapid development of clinical trials in which autologous 
hematopoietic cells were injected intramuscularly into the ischemic limb.  These 
studies utilize autologous bone marrow mononuclear cells (BM-MNCs) obtained 
directly from bone marrow aspirates or G-CSF-mobilized peripheral blood-
mononuclear cells (PB-MNCs).    In one group of trials, summarized in Table 1, 
autologous BM-MNCs were injected intramuscularly into the ischemic limb of 
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patients with critical limb ischemia.  In each of these trials therapeutic benefits were 
observed in the treatment group as measured by a variety of indicators including 
improvements in ankle-brachial index, mean walking distance, and collateral 
formation.  While these promising findings have been reported for critical limb 
ischemia, similar myocardial infarction trials have yielded disappointing results.  
Little efficacy has been observed using either BM-MNC or PB-MNC therapies 
(Dimmeler, 2008).  Therefore an understanding of the specific pro-angiogenic 
populations contained within the mononuclear cell compartment and the mechanism 
by which these cells promote angiogenesis may reveal important information about 
how to improve the design of these therapies for myocardial infarction patients.      
 
 
1.3  Monocyte biology 
1.3.1  Development and functions 
Monocytes are mononuclear cells that develop from a common myeloid 
progenitor in the bone marrow and are released into the blood under both basal and 
pathogenic conditions (Fogg, 2006).  Monocytes comprise approximately 5-10% of 
the total leukocyte population in the blood where they exhibit a relatively brief 
lifespan.  Monocytes in mice and humans demonstrate a half-life of 17 hours (van 
Furth, 1989) and 71 hours (Whitelaw, 1972), respectively.  Upon recruitment to 
peripheral tissues, monocytes can follow one of two differentiation pathways 
generating either macrophages or dendritic cells (DCs).  Macrophages engulf dead 
cells and debris, proteolytically degrade this cellular material, and release cytokines 
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which further promote the clearance of dead cells.  After processing this cellular 
debris, macrophages do not process or present antigens or generate a T cell response 
(Zammit, 2005).  DCs likewise phagocytose cellular debris but in addition they 
process and present them to T cells via MHC molecules (Trombetta, 2003).  The 
migration properties of these cell types likewise differ: while macrophages remain 
largely confined to tissues, DCs can traffick from the tissues to peripheral lymphoid 
organs.  In addition to deriving from bone marrow/blood precursors, some 
macrophage populations, such as the pulmonary macrophages are known to self-
renew from local precursors (Tarling, 1987).  After emigrating from the blood to 
tissues, macrophages can exhibit any of a wide array of phenotypes depending on 
local signals as outlined below.   
 
1.3.2  M1/M2 polarization 
In response to a variety of stimuli, monocytes are recruited from the bone 
marrow to the blood and subsequently to peripheral tissues where they can 
differentiate into several effector macrophage subsets.  Infectious and pro-
inflammatory stimuli generate signals which drive macrophages down the classical 
activation or M1 pathway.  In vitro, cells exhibiting an M1 phenotype can be 
generated by treating with interferon-γ (IFN-γ) or lipopolysaccharide (LPS).  M1 
polarized macrophages produce a panoply of inflammatory mediators and utilize the 
nitric oxide synthase pathway to generate large amounts of nitric oxide (NO).  
Accordingly, nitric oxide measurements are frequently used as an assessment of 
polarization to the M1 phenotype (Mills, 2000).  Conversely, macrophages can 
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undergo alternative activation to polarize along the M2 pathway.  Alternative 
activation occurs biologically upon infection with parasitic helminths or in response 
to allergens.  This subset of macrophages is referred to at M2a.  In addition, M2 
polarization can occur in response to activation by immune complexes, generating a 
subset called M2b.  Lastly, the M2 phenotype can be generated in response to IL-10 
production at the resolution of inflammation (Kreider, 2007).  In keeping with in vivo 
observations, polarization towards the M2 phenotype can be driven in vitro by 
treating with IL-4, IL-13, or IL-10.  M2 polarized macrophages utilize the arginase 
pathway and expression of arginase 1 (Arg1) is a distinct marker for this cell type.  
Additionally, expression of the markers Ym1/chitinase and FIZZ1 are widely 
accepted as M2 markers across all M2 subsets and are upregulated in response to the 
vast majority of helminth infections (Martinez, 2009). 
Genetic mouse models for M1 or M2 polarization have been described, but 
are wrought with important caveats.  Mice lacking Src homology inositol phosphotase 
(SHIP) demonstrate a skewing towards increased M2 polarization as SHIP has been 
found to repress alternative activation in macrophages in vitro (Rauh, 2005).  In 
addition, PPAR-gamma deficiency has been shown to result in preferential M1 
macrophage polarization (Odegaard, 2007).  Interestingly, these phenotypes are 
highly dependent upon mouse strain.  For example, in the Th1-permissive Balb/c 
mouse strain, PPAR-gamma deficiency results in increased M1 polarization, however 
in the Th1-resistant C57Bl/6 mouse strain this phenotype is not observed.   
While M1-polarized macrophages clearly play a role in inflammatory 
processes, the role of M2-polarized macrophages is less clear.  M2a macrophages in 
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concert with Th2 cells to elicit antibody-mediated immunity which allows antibodies 
to coat invading parasites such that they can be cleared via a process referred to as 
antibody-dependent cell-mediated cytotoxicity (ADCC).  Monocytes exhibiting an 
M2 phenotype have been extensively reported in a variety of tumor models (Nardin, 
2008).  
The ability of M1 or M2 macrophage subsets to influence angiogenesis 
outside of the tumor microenvironment has not been extensively studied, however 
one report indicates that IL-4-inducted M2 macrophages elicited a 3-fold greater 
proliferation in endothelial cells in vitro compared to IFN-g-elicited M1 macrophages 
(Kodelja, 1997).  The studies described in Chapter 3 will assess M1 and M2 
polarization phenotypes in an ischemic setting. 
 
 
1.3.3  CX3CR1 monocyte subsets  
Monocytes are a widely heterogeneous cell population in which the full extent 
of existing subsets and the plasticity between subsets is largely unknown.  One major 
subset designation in monocytes has been recently described based upon differential 
expression of the cell surface markers CX3CR1 and Gr-1 (Table 2).  In the bone 
marrow, monocytes can be divided into two distinct populations based upon these 
markers, namely CX3CR1hiGr-1- and CX3CR1loGr-1+ subsets.  The CX3CR1loGr-1+ 
subset is referred to as the inflammatory subset, due to the ability of these cells to 
migrate to the peritoneum in response to intraperitoneal thioglycollate.  In addition, 
these cells express the adhesion markers VCAM-1 and L-selectin, as well as the 
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chemokine receptor CCR2.  In contrast, cells of the CX3CR1hiGr-1- subset do not 
traffic to the peritoneum in response to thioglycollate treatment and do not express 
the adhesion markers or chemokine receptors observed in the inflammatory subset 
(Geissmann, 2008).  Based on these observations, this subset is referred to as the 
resident subset.  While the precise function of this subset is unclear, a recent study 
has suggested that the resident monocyte subset patrols blood vessels, allowing rapid 
tissue invasion and subsequently give rise to macrophages while inflammatory 
monocytes reach the inflammatory site at a later time and differentiate into 
inflammatory DCs (Auffray, 2007).  Subsets analogous to the mouse inflammatory 
and resident subsets have been described in humans in which a CD14hiCD16- 
population resembles the inflammatory monocyte population while CD14+CD16+ is 
functionally comparable to the resident subset (Table 3) (Zeigler, 2007). 
  The bone marrow is made up largely of the CX3CR1loGr-1+ inflammatory 
subset while the resident subset dominates in the peripheral blood.  Several studies 
have indicated that the inflammatory population in the bone marrow may convert into 
the resident population in the peripheral blood based upon labeling and tracking 
studies (Tacke, 2006; Arnold, 2007).    Another study utilizing a mouse model of 
myocardial infarction has indicated that the inflammatory subset is selectively 
recruited first and that these cells exhibit phagocytic and proinflammatory functions 
and that subsequently the healing myocardium recruits monocytes of the resident 
subset which mediate angiogenesis and the deposition of collagen (Nahrendorf, 
2007).  While no studies have directly examined the contribution of the inflammatory 
and resident subsets to angigogenesis, in the ApoE-/- atherosclerosis-prone mouse 
  
13
model, a skewing towards the CX3CR1loGr-1+ inflammatory monocyte subset was 
observed in the blood and these cells also preferentially accumulated in the 
atherosclerotic lesion (Tacke, 2007).  Further studies are required to determine if this 
subset is responsive to specifically responsive to ischemic signals or if the 
accumulation of the cells is in response to inflammatory signals.  
 
 
 
 
1.3.4  Tie2 monocyte subset 
Recent studies have revealed a potently angiogenic monocyte subset that 
expresses the receptor tyrosine kinase Tie2.  The Tie2 receptor binds two major 
ligands:  the agonist ligand angiopoietin-1 (Ang1) and the antagonist ligand 
angiopoietin-2 (Ang2).  Binding of Ang1 to Tie2 receptor strengthens interactions 
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between endothelial cells and extracellular matrix (Thurston, 2000).  Ang2 competes 
for binding with Tie2 preventing the binding of Ang1, thus leading to destabilization 
of vessels (Maisonpierre, 1997).  However, in vitro, Ang-2 stimulates endothelial 
cells migration and tube cell formation (Teichert-Kuliszewska, 2001).  Roughly 2-5% 
percent of bone marrow cells have been shown to express Tie2.  Flow cytometic 
analysis revealed that these Tie2+ cells present in the bone marrow were comprised of 
both endothelial cells (<5% CD31+CD45−) and hematopoietic cells (>95% CD45+).  
Tie2-expressing CD45+ hematopoietic cells were found to be enriched for Sca-1+ (
30%) and c-kit+ ( 50%) progenitors (De Palma, 2003).  In the peripheral blood, 
Tie2-expressing monocytes (TEMs) have been shown to comprise 2-7% of the total 
circulating monocytes in healthy human subjects (Venneri, 2007) as well as in mice 
(Lewis, 2007).  TEMs in the peripheral blood largely did not express the HSC/HPC 
markers c-kit (95% c-kit−) and Sca-1 (>70% Sca-1−).  Interestingly, circulating TEMs 
were found to exhibit a CCR2–, L-selectin-, CCR5+ phenotype—a surface profile 
previously associated with resident monocytes (Gordon, 2005).   
  While TEMs comprise only a small fraction of blood monocytes, they are 
have been found to be enriched in a variety of tumor environments.  55% and 70% of 
the CD14+ monocytes present in both a colorectal and lung carcimona expressed 
Tie2.  It is thought that these TEMs play an important role in vascularizing tumors 
based on several lines of evidence.  For example, U87 tumor cells coinjected with 
human CD14+Tie2+ monocytes led to larger and more highly vascularized tumors 
than those observed in mice receiving U87 cells alone (De Palma, 2009).  In addition, 
in a knockout mouse model lacking TEMs, there was a complete prevention of human 
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glioma neovascularization in the mouse brain as well as substantial tumor regression 
(De Palma, 2005).  It is currently unknown whether TEMs represent a unique 
monocyte lineage or if this phenotype is induced by the tumor microenvironment.       
 
1.4  CX3CR1/fractalkine receptor 
Fractalkine or CX3CL1 is CX3C motif chemokine which is produced by 
macrophages, activated vascular endothelial cells, smooth muscle cells, epithelial 
cells, dendritic cells, and neurons (Landsman, 2009).  CX3CR1 is the sole known 
receptor for fractalkine ligand and is expressed on blood monocytes, T cells, DC 
subsets, and natural killer (NK) cell subsets.  Fractalkine ligand is a transmembrane 
mucin-like stalk which mediates integrin independent adhesion to leukocytes 
expressing CX3CR1 (Bazan, 1997).  CX3CL1 can also be cleaved and secreted, and 
in its secreted form it acts as a chemoattractant for cells bearing its cognate receptor 
(Garton, 2001; Hundhausen, 2003).  
Expression of fractalkine is induced in inflammatory conditions downstream 
of TNF-α and IL-1 production (Bazan, 1997).  IFN-g has been shown to increase 
fractalkine expression in epithelial cells and dermal fibroblasts (Fujimoto, 2001; 
Fahy, 2003) acting through the STAT1 signaling pathway (Lombardi, 2008).  A 
recent study has demonstrated that in the absence of either CX3CR1 or CX3CL1 
there is a reduction in circulating monocyte levels at steady state as well as in the 
inflammatory setting present in ApoE-/- atherosclerosis-prone mice (Landsman, 
2009).  This study also reported that overexpression of the cell survival factor Bcl2 in 
CX3CR1-/- or CX3CL1-/- mice restored monocyte recruitment, suggesting that the 
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CX3CR1 pathway promotes cell survival.  In a model for wound healing, CX3CR1 
was found to play a critical role as CX3CR1-/- mice exhibited defects in macrophage 
infiltration, VEGF production, collagen deposition, and neovascularization (Ishida, 
2008).     
  A variety of studies have indicated that fractalkine and its receptor may be 
induced in response to hypoxia and may play an important role in blood vessel 
growth.  Specifically, hypoxia has been shown to inhibit the IFN-γ-induced 
expression of fractalkine in HUVEC; however this inhibition is reversible as the 
reintroduction of oxygen increases fractalkine levels (Yamashita, 2003).  The addition 
of exogenous fractalkine ligand has been shown to induce new vessel formation in 
vitro using the rat aortic ring and chick chorioallantoic membrane in vitro assays 
(Ryu, 2008).  This vessel formation was associated with upregulation of HIF-1a and 
VEGF-A.  The role of CX3CR1 in mediating post-ischemic angiogenesis varies 
according to the models tested.  In a mouse model for retinal vascular repair, 
CX3CR1 signaling was shown to have no role in revascularizing injured retinal tissue 
(Zhao, 2009).  In contrast CX3CR1-/- mice demonstrated reduced macrophage 
accumulation as well as decreased injury in models for kidney ischemia/reperfusion 
(Li, 2008) and focal cerebral ischemia (Denes, 2008).   Interestingly, bone marrow 
transplantation experiments demonstrated that mice lacking CX3CR1 in the 
hematopoietic compartment were able to promote blood vessel growth within an 
implanted Matrigel/fractalkine matrix whereas mice lacking CX3CR1 in all tissues 
demonstrated no blood vessel growth (Ryu, 2008).  This finding suggests that 
CX3CR1 signaling by endothelial cells may be a greater contributor to angiogenesis 
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than signaling by this receptor on hematopoietic cells, however data from other 
angiogenic models is currently lacking.   
   In addition to an accumulating body of evidence that fractalkine may play an 
important role in angiogenesis, several studies have linked fractalkine and its receptor 
to atherosclerosis susceptibility.  Polymorphisms in this gene which reduce the ability 
of CX3CR1 to bind to its ligand are associated with a reduced risk for atherosclerosis 
in humans (Lesnik, 2003).  In addition CXCL1 expression has been observed in both 
macrophages and coronary artery smooth muscle cells in the vessels of 
atherosclerotic but not normal patients (Wong 2003, Lucas 2002).  While the role of 
CX3CR1/CX3CL1 in leading to atherosclerosis is unclear a recent study has 
demonstrated that the lipid components of low density lipoprotein (LDL) activate 
peroxisome proliferator-activated receptor-γ (PPAR-γ) in macrophages leading to 
decreased CCR2 expression (and therefore reduced CCR2-dependent migration) and 
increased CX3CR1 expression leading to adhesion to the vessel wall (Barlic, 2006).  
CX3CL1-/-ApoE-/- mice demonstrated no reduction in the number of circulating 
monocytes, however there was a significant reduction in the number of macrophages 
which infiltrated the atherosclerotic lesion (Saederup, 2007).  This finding suggests a 
role for CX3CL1 in the capture and retention of monocytes by the endothelium and 
not in their ability to traffick from the bone marrow to the periphery.  Taken together 
the aforementioned studies indicate a clear role for the CX3CR1/CX3CL1 interaction 
in the retention of monocytes at inflammatory and ischemic lesions. 
 
1.5  Apolipoprotein A1 
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ApoA1 is the major protein component of high density lipoprotein (HDL).  
ApoA1 is synthesized in the liver and small intestine, exported and associates with 
lipids extracellularly.  The primary function of HDL is to promote reverse cholesterol 
transport from the tissues to bile.  HDL-associated ApoA1 is classically regarded as a 
negative acute-phase protein, a term assigned to serum proteins whose levels are 
decreased by at least 25% during acute inflammation (Gabay, 1999).  In keeping with 
its anti-inflammatory designation, ApoA1 has been shown to inhibit monocyte 
activation in vitro (Murphy, 2008).  Additionally, gene transfer of ApoA1 led to 
reductions in macrophage accumulation in several mouse models of atherosclerosis 
(Tangirala, 1999; Paszty, 1994).  Likewise, administration of ApoA1 significantly 
limited macrophage-related pathology in mouse models of kidney 
ischemia/reperfusion injury (Shin, 1998), myocardial infarction (Gu, 2007), and 
stroke (Paterno, 2004). 
While the above studies indicate an anti-inflammatory role for ApoA1, recent 
evidence suggests that the precise relationship of HDL/ApoA1 to the regulation of 
inflammation may, in fact, be more complex.  HDL has been shown to be both pro-
inflammatory and anti-inflammatory depending on the model tested.  On the whole it 
is accepted that HDL prevents inflammation in the absence of systemic inflammation 
but becomes pro-inflammatory in response to systemic inflammation or an acute 
phase response (Navab, 2005; van Lenten, 1995).  For example, when mice were 
subjected to a viral pneumonia, HDL became pro-inflammatory and resulted in a 
marked increase in IL-6 production and in macrophage trafficking to the infected 
areas (van Lenten, 2002).  In this same study, when mice were treated with an ApoA1 
  
19
mimetic peptide, a dramatic reduction in macrophage accumulation and IL-6 
production was observed.  Interestingly, increased levels of ApoA1 have been 
observed in the synovial fluid of rheumatoid arthritis patients concomitant with a 
reduction in serum levels of this protein (Oliviero, 2009; Ananth, 1993).  It is unclear 
whether the redistribution of this protein from the circulation to the inflammed joint is 
a mechanism to reduce inflammation or if it is, in fact, contributing to the pathology.   
With respect to vascular models, one study has demonstrated that ApoA1 
stimulates endothelial cell migration in vitro (Seethram, 2006).  Additionally, mice 
lacking ApoA1 demonstrate impaired revascularization in response to carotid artery 
injury and this defect is rescued by reconstitution of ApoA1 expression by gene 
transfer (Seetharam, 2006).  Another study revealed that treatment of mice with 
recombinant HDL post-hindlimb ischemia significantly improves blood flow 
recovery in an endothelial nitric oxide synthase (eNOS)-dependent fashion (Sumi, 
2007).  Based on these studies and findings described above, ApoA1 clearly plays a 
role in the regulation of revascularization as well as macrophage recruitment.  In 
Chapter 2 we will examine the contribution of this protein to the recovery from 
hindlimb ischemia. 
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1.6  Summary 
This study will center on defining the proangiogenic subsets of monocytes and 
also exploring the mechanism by which these cells improve angiogenesis.  Three 
main questions will be addressed: 
 
1.  What subset of monocytes is angiogenic? 
2.  What factors released by monocytes accelerate angiogenesis? 
3.  How do signals generated by ischemia impact the phenotype of endogenous, bone 
marrow resident monocytes? 
 
In Chapter 2 we will define the subset of monocytes responsible for 
angiogenesis and examine the importance of two factors with a previously 
undetermined role in post-ischemic angiogenesis.  In Chapter 3 we will assess 
differences between non-ischemic donor and ischemia-conditioned bone marrow 
monocytes.  Finally, in Chapter 4 we will summarize our results, discuss the 
significance of this work, and outline future studies.   
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2.1  ABSTRACT 
Monocytes are a widely heterogeneous cell population which has been shown to 
significantly accelerate angiogenesis in a variety of models.  Differences in the ability 
of various monocyte subsets to mediate revascularization have not been previously 
investigated.  Herein, we address the two subsets of monocytes designated based on 
differential expression of CX3CR1 and Gr-1, the CX3CR loGr-1+ inflammatory subset 
and the CX3CR1hiGr-1- resident subset.  Using a mouse model for hindlimb ischemia, 
we demonstrate that an adoptive transfer of the inflammatory subset, but not the 
resident subset, significantly enhances revascularization post-ischemia.  Additionally, 
we show that the inflammatory subset of monocytes is selectively recruited from the 
bone marrow to the blood upon induction of ischemia.  Accordingly an accumulation 
of monocytes of the inflammatory subset is observed at the ischemic lesion at all 
analyzed timepoints post-hindlimb ischemia.  Lastly we demonstrate that the efficacy 
of an adoptive transfer of inflammatory monocytes may be due, at least in part, to 
increased expression of the fractalkine receptor CX3CR1 as well as to increases in 
local concentrations of the angiogenic factors MCP-1, VEGF, MMP-9 and ApoA1.   
 
2.2  INTRODUCTION 
Peripheral arterial disease is an atherosclerosis-associated syndrome which 
affects nearly 15% of the United States population over the age of 55 (Weitz, 1996).  
Critical limb ischemia is a severe manifestation of peripheral arterial disease and is a 
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leading cause of limb amputation.  Various strategies have been used in an effort to 
restore angiogenesis in the setting of critical limb ischemia, including cytokine and 
cell therapies.  Treatment with growth factors alone, namely VEGF (Rajagopalan, 
2003) and rFGF (Lederman, 2002) has demonstrated little efficacy in clinical trials.  
Based on the assumption that treatment with a single growth factor is unlikely to 
recapitulate all the signals necessary for angiogenesis, recent studies have focused on 
the ability of hematopoietic cell-based therapies to mediate revascularization.  
Notably, several studies have demonstrated that intramuscular injections of bone 
marrow mononuclear cells (BM-MNCs) or apheresed, G-CSF-mobilized peripheral 
blood-mononuclear cells (PB-MNCs) can improve revascularization as assessed by 
several indicators including improvement of ischemic ulcers, increase in maximum 
walking distance, and a reduction in amputations (Al Mheid, 2008).  Mobilization of 
the patients’ own mononuclear cells via G-CSF (Arai, 2006) or GM-CSF (van Royen, 
2005) has likewise shown promise as a treatment for critical limb ischemia.  
However, as a non-specific and widespread mobilization or local injection of a 
heterogeneous population of inflammatory cells may have deleterious side effects, 
particularly within the context of atherosclerosis, there exists a demand for cell-based 
therapies in which a small population of highly angiogenic cells is targeted to the 
ischemic tissue.   
Recent studies by our laboratory have demonstrated that of the major cell 
types contained within the mononuclear cell fraction, monocytes exhibit the most 
potent angiogenic activity (Capoccia, 2006).  Monocytes play a variety of roles in the 
angiogenic process, including the secretion of a variety of factors including VEGF, 
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bFGF, TGF-a, GM-CSF, IL-8, and PDGF.  These factors promote proliferation and 
migration of endothelial cells as well as tube formation (Sunderkotter, 1994).  
Activation of endothelial cells by these cytokines induces production of VEGF and 
MCP-1, providing a positive amplification loop leading to the recruitment of 
additional monocytes (Shireman, 2007).  Additionally, monocytes express 
metalloproteases and serine proteases which play a critical role in degradation of the 
extracellular matrix, thus generating an appropriate scaffolding upon which new 
vessels can form (Moldovan, 2005).  Mice subjected to ischemia exhibit a marked 
endogenous monocytic response, consisting of increased production in the bone 
marrow and trafficking to the lesion (Capoccia, 2008).  Additionally, ablation of 
macrophages is associated with a significant reduction in post-ischemic angiogenesis 
(Heil, 2002; DiPietro, 1993; Brechot, 2008).  Therefore a determination of the 
mechanisms governing monocyte recruitment and retention at ischemic sites as well 
as an understanding of what constitutes a proangiogenic phenotype may reveal 
important therapeutic strategies for the treatment of ischemic disorders.  
Geissmann and colleagues described two unique monocytic populations 
present in the bone marrow and blood based on differential expression of the 
fractalkine receptor, CX3CR1, and Gr-1 (2003).  The fractalkine receptor CX3CR1 
binds to fractalkine ligand (CX3CL1) and this interaction promotes adhesion.  Both 
CX3CR1 and its ligand are expressed on hematopoietic cells, including monocytes, as 
well as endothelial cells.  Cells with a CX3CR1loGr-1+ phenotype were named 
“inflammatory” based on the observation that these cells traffick from the bone 
marrow to the peritoneum in response to intraperitoneal injections of thioglycolate.  
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In contrast, cells exhibiting the CX3CR1hiGr-1- phenotype, did not respond to 
challenge with thioglycolate and were thus referred to as the “resident” subset.  A 
recent study has indicated that cells of the inflammatory subset may convert into 
resident cells in the periphery, however the precise relationship between these subsets 
is not fully defined (Tacke, 2006).   
Herein, we provide evidence that the inflammatory subset of monocytes is 
preferentially recruited from the bone marrow to the peripheral blood to the site of 
ischemia.  In accordance with this finding, an adoptive transfer inflammatory 
monocytes significantly improves revascularization post-hindlimb ischemia (HLI).  
This improvement is associated with an increased influx of endogenous monocytes to 
the ischemic lesion as well as increased local production of the known angiogenic 
factors vascular endothelial growth factor-A (VEGF-A), monocyte chemotactic 
protein-1 (MCP-1),  matrix metalloprotease-9 (MMP-9), as well as of apolipoprotein 
A1 (ApoA1).  Additionally, we show that an adoptive transfer of ApoA1-/- 
inflammatory monocytes does not improve revascularization post-HLI, demonstrating 
for the first time an important role for this protein in mediating post-ischemic 
angiogenesis.     
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2.3  MATERIALS AND METHODS  
 
Mice.  ApoA1-/- mice on a C57BL/6 background were obtained from The Jackson 
Laboratory (Bar Harbor, ME, USA). CX3CR1GFP/+ and CX3CR1GFP/GFP mice on a 
C57BL/6 background were a generous gift from Dr. Dan Littman (Skirball Institute of 
Biomolecular Medicine, New York University School of Medicine, New York, NY, 
USA). Mice were housed in a specific pathogen-free environment. The Washington 
University Animal Studies Committee (St. Louis, MO, USA) approved all 
experiments.  
Murine hindlimb ischemia model.  The hindlimb ischemia surgical procedure was 
performed as described previously (Couffinhal, 1998). In brief, an incision was made 
in the skin at the mid-portion of the right hindlimb overlying the femoral artery, and 
the femoral artery and vein were then dissected free from the nerve, and the proximal 
portion of the femoral artery and vein ligated with 6-0 silk sutures. The distal portion 
of the saphenous artery and vein and remaining arterial and venous side branches 
were ligated, followed by their complete excision from the hindlimb. The overlying 
skin was then closed using Nexaband veterinary glue (Abbott Animal Health, Abbott 
Park, IL, USA).  
Laser Doppler perfusion imaging.  Blood perfusion in the hindlimb was monitored by 
laser Doppler imaging (MoorLDI-2, Moor Instruments, UK). Before initiating 
scanning, mice were anesthetized with ketamine/xylazine and placed on a heating 
plate at 37°C to minimize temperature variations. For each time-point, the laser 
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Doppler image obtained was analyzed by averaging the perfusion, expressed as the 
relative unit of flux as determined by Moor Instruments, over the surface of the 
ischemic and nonischemic foot. To control for ambient light and temperature, 
calculated perfusion was expressed as the flux ratio between the ischemic and 
nonischemic limbs.  
Inflammatory and resident monocyte subset isolation.  Bone marrow mononuclear 
cells from CX3CR1GFP/+ mice were incubated at 4°C with PE-conjugated Gr-1 
antibody (PharMingen). CX3CR1loGr-1+ and CX3CR1hiGr-1– monocytes were 
isolated using a MoFlo high-speed flow cytometer (Dako Cytomation, Fort Collins, 
CO, USA).  
Adoptive transfer of CFSE-labeled cells.  Bone marrow was harvested from the 
femurs of donor mice, and mononuclear cells were isolated by centrifugation across a 
1.011 density gradient (Histopaque, Sigma-Aldrich, St. Louis, MO, USA) at 1700 x g 
for 30 min. Mononuclear cells were then incubated with 2.5µM CFSE in PBS for 10 
min at 37°C. CFSE-labeled mononuclear cells (1x106) were administered i.v. into 
recipient mice 24 h after the induction of hindlimb ischemia; this cell dose is the 
minimum number that consistently stimulated angiogenesis in the hindlimb ischemia 
model.  
Flow cytometry.  The adductor muscle from ischemic and nonischemic hindlimbs was 
surgically isolated after hindlimb ischemia and then treated with 3 mg/ml Type I 
collagenase (Worthington Biomedical Corp., Lakewood, NJ, USA) for 40 min at 
37°C. After filtering through a 50-µm cell strainer (Partec, Munster, Germany), cells 
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were incubated with Fc block (Miltenyi Biotec, Auburn, CA, USA) for 10 min at 4°C, 
followed by incubation with PE-conjugated antibodies to Gr-1, F4/80, CD3, B220, or 
NK1.1 (PharMingen, San Diego, CA, USA). Cells were analyzed on a FACScan flow 
cytometer (Becton Dickinson, Franklin Lakes, NJ, USA). Data are reported as the 
total number of the indicated cell type recovered from an entire adductor muscle.  
Unbiased screen for soluble factors.  Following digestion of adductor muscle with 
collagenase to generate a single-cell suspension, cells and debris were removed by 
centrifugation at 500 x g for 5 min. The cell-free tissue supernatant was recovered and 
analyzed using a multiplexed ELISA assay for 58 unique soluble factors (Rules Based 
Medicine, Austin, TX, USA).   
Statistical analysis.  Statistical significance was determined by a two-way ANOVA 
analysis or by a two-sided Student’s t-test.  
 
2.4  RESULTS 
 
2.4.1  Monocytes are recruited to ischemic tissue post-HLI.  In order to determine 
if adoptively transferred monocytes home to the ischemic lesion, donor BM-MNCs 
were labeled with CFSE and were injected intravenously into ischemic recipients at 
24 hours post-HLI.  The ischemic adductor muscle was harvested at several time 
points post-ischemia, homogenized, and cell populations contained in this fraction 
were analyzed by flow cytometry.  As shown in Figure 2.1A, adoptively transferred 
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monocytes to home to ischemic tissue, with a peak influx of 2.5x104 cells observed at 
24 hours post-adoptive transfer.  Likewise, contaminating neutrophils present in BM-
MNC preparations were observed to home to the ischemic adductor muscle (Figure 
2.1B).  Interestingly, the adoptive transfer of BM-MNCs lead to increased recruitment 
of CFSE- endogenous monocytes to the ischemic adductor muscle with peak numbers 
observed at 24 hours post-adoptive transfer (Figure 2.1.C).  These data indicate that 
both monocytes and neutrophils contained within the adoptively transferred BM-
MNC fraction home to the site of ischemia, and that a specific recruitment of 
additional endogenous monocytes is observed. 
  
2.4.2  An adoptive transfer of the inflammatory, but not resident, subset of 
monocytes significantly improves revascularization post-HLI.  The recent 
designation of the inflammatory and resident subsets of monocytes is based on the 
ability of these subsets to traffick in response to thioglycollate.  The contribution of 
these particular subsets in responding to alternative signals, such as ischemia, has not 
been previously examined.  In order to determine if the inflammatory and resident 
monocyte subsets differ in their ability to promote post-ischemic angiogenesis, we 
sort-purified these populations and adoptively transferred them into ischemic 
recipients.  Revascularization of ischemic recipients was assessed over a 14-day time 
course using laser Doppler imaging.  While an adoptive transfer of resident 
monocytes showed no improvement over PBS-treated controls, an adoptive transfer 
of inflammatory monocytes lead to a significant acceleration of revascularization 
(Figure 2.2).  This finding indicates that the CX3CR1loGr-1+ inflammatory subset is 
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uniquely responsible for the enhanced revascularization observed upon an adoptive 
transfer of unfractionated monocytes.   
 
2.4.3  The inflammatory subset of monocytes is selectively mobilized from the 
bone marrow into the blood post-HLI.  Having determined that an adoptive transfer 
of inflammatory monocytes significantly increases revascularization post-HLI, we 
next assessed the contribution of inflammatory and resident monocyte subsets to the 
endogenous response to ischemia.  At baseline, the resident monocyte subset 
dominates in the peripheral blood while, the inflammatory subset comprises the 
majority of bone marrow monocytes.  However, in response to hindlimb ischemia, an 
increase in the number of inflammatory cells in the blood is observed (Figure 2.3A) 
concomitant with an increase in the production of this subset in the bone marrow 
(Figure 2.3B).  These data indicate that the inflammatory subset of monocytes is 
selectively mobilized from the bone marrow into the peripheral blood in response to 
hindlimb ischemia.       
2.4.4  Monocytes of the inflammatory subset accumulate at the ischemic lesion 
post-HLI.  As monocytes of the inflammatory subset preferentially mobilize from the 
bone marrow to the blood in response to hindlimb ischemia, we next asked if this 
subset likewise accumulates at the ischemic lesion.  In fact, the monocytic infiltrate in 
the ischemic adductor muscle was largely comprised of the inflammatory subset.  
Around 106 inflammatory monocytes were observed at the peak time of influx, 
whereas levels of resident monocytes peaked at only around 105 cells (Figure 2.4).  
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This data suggests that inflammatory monocytes are the major subset mediating repair 
at the site of ischemia in this model.  This finding contrasts with chronic models of 
ischemia in which a bimodal “switch” from inflammatory to resident monocyte 
infiltrate is observed (Nahrendorf, 2007; Arnold, 2007).    
 2.4.5 Bone marrow resident monocytes decrease expression of CX3CR1 upon 
induction of ischemia and CX3CR1-/- monocytes exhibit a reduced ability to 
improve angiogenesis.  In order to understand why the trafficking of a small number 
of adoptively-transferred donor monocytes, representing only 0.1-1% of the total 
monocytes present in the ischemic lesion, so potently accelerates revascularization we 
set out to assess phenotypic differences between donor monocytes and endogenous 
monocytes.  Interestingly, we observed that upon induction of ischemia, expression of 
the fractalkine receptor CX3CR1 is markedly reduced (Figure 2.5A).  As CX3CR1 is 
known to play a role in adhesion of monocytes to endothelium and also in stimulating 
endothelium to produce a variety of angiogenic factors, we set out to assess if the 
downregulation of CX3CR1 which occurs as monocytes leave the bone marrow 
impairs the downstream angiogenic capacity of these cells.  To test this, we sort-
purified monocytes from a CX3CR1-/- donor and adoptively transferred these cells 
into ischemic recipients.  In fact, these cells did exhibit a slight, but statistically 
significant, defect in accelerating revascularization compared to wild type controls 
(Figure 2.5B).  This finding suggests that the loss of CX3CR1 expression that occurs 
as monocytes are mobilized from the bone marrow to the periphery may partially 
explain the loss of angiogenic capacity of these cells compared to donor cells which 
express high levels of this receptor.   
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2.4.6.  Local production of VEGF, MCP-1, MMP-9, and apolipoprotein A1 is 
increased post-adoptive transfer.  As CX3CR1 expression in endogenous 
monocytes appears to play only a partial role in mediating the proangiogenic effects 
of monocytes, we next performed an unbiased screen to determine what factors are 
produced locally which may impact revascularization.  An unbiased ELISA-based 
screen for 58 unique soluble factors was performed on cell-free muscle supernatants 
obtained from the ischemic adductor muscles of mice undergoing HLI only (poor 
blood flow recovery) and from mice receiving HLI plus an adoptive transfer of BM-
MNCs (improved blood flow recovery).  The screen indicated that levels of the 
proangiogenic factors VEGF (Figure 2.6A), MCP-1 (Figure 2.6B), and MMP-9 
(Figure 2.6C) as well as the major protein component of HDL, apolipoprotein A1 
(Figure 2.6D) were increased upon adoptive transfer.  As VEGF, MCP-1, and MMP-9 
have well-described roles in post-ischemic angiogenesis, we decided to examine the 
importance of apolipoprotein A1 in mediating the potent pro-angiogenic effect of a 
monocytic adoptive transfer.     
2.4.7.  An adoptive transfer of apolipoprotein A1-deficient monocytes does not 
improve revascularization post-HLI.  ApoA1 is the major protein component of 
HDL known to be largely synthesized by hepatocytes in the liver and then exported 
into the circulation where it assembles with the lipid components of HDL (ref).  The 
ApoA1 lipid complex classically is known to play an important role in reverse 
cholesterol transport.  Synthesis of ApoA1 by monocytes and its role in post-ischemic 
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angiogenesis has not been previously described.  In order to determine if production 
of ApoA1 by monocytes is necessary for monocytes to mediate their angiogenic 
effect, we sort-purified inflammatory monoctyes from ApoA1-/- mice and adoptively 
transferred them into ischemic recipients.  Interestingly, an adoptive transfer of 
monocytes lacking ApoA1 was not sufficient to enhance revascularization compared 
to wild type controls (Figure 2.7).  This data indicates an essential role for ApoA1 in 
the angiogenic repair capacity of monocytes.   
 
2.5  DISCUSSION 
BM-MNCs have demonstrated efficacy in the treatment of a variety of 
ischemic disorders in both mice and humans.  Many of these studies have centered on 
the role of progenitor populations present in the BM-MNC fraction and their ability to 
differentiate into endothelial cells.  However, recent work by our laboratory has 
demonstrated that the monocyte fraction contained within BM-MNCs potently 
enhances revascularization following hindlimb ischemia (Capoccia, 2006).  We 
observed that adoptively transferred monocytes home to the site of ischemia and also 
recruit additional endogenous monocytes to the lesion (Figure 2.1).   
A further examination of monocyte subsets revealed that only the 
inflammatory and not the resident subset of monocytes is competent to accelerate 
revascularization (Figure 2.2).  Additionally, the inflammatory subset of monocytes 
likewise is selectively recruited from the bone marrow into the blood upon induction 
of ischemia and this is the major subset that accumulates at the ischemic lesion at all 
time points post-HLI.  In several other models including myocardial infarction 
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(Nahrendorf, 2007) as well as a muscle injury model (Arnold, 2007), inflammatory 
monocytes dominate the early time points while the resident population comprises the 
majority of the infiltrate at late timepoints.  Interestingly, Tie2-expressing monocytes 
(TEMs), thought to be potently angiogenic in tumor models, are thought to fall within 
the resident Gr-1- subset of monocytes (Venneri, 2007).  Our finding underscores the 
potential differences in tumor versus ischemia-driven angiogenesis.  These data 
provide the first evidence that the CX3CR1loGr-1+ inflammatory subset is the major 
contributor to angiogenic repair in response to acute ischemia.         
CX3CR1 is the receptor for the fractalkine ligand CX3CL1 which is 
expressed as a transmembrane protein on a mucin-like stalk.  Interaction of CX3CR1 
with this membrane-bound ligand allows for integrin-independent adhesion.  The 
membrane-bound form of CX3CL1 can also be cleaved by metalloproteases 
generating free CX3CL1 which can then act as a chemoattractant.  CX3CR1-/- and 
CX3CL1-/- mice both demonstrate a reduction in circulating resident monocytes and 
normal numbers of inflammatory monocytes.  A recent study has demonstrated that 
this is due to the critical Bcl2-dependent survival signals generated by the 
CX3CR1/CX3CL1 interaction in the resident monoctyes (Landsman, 2009).  
Interestingly, local injections of CX3CL1 lead to improved blood flow recovery in a 
rat model of hindlimb ischemia (Ryu, 2008).  As CX3CR1 expression was markedly 
decreased in bone marrow monocytes post-HLI, but intact in donor monocytes from 
mice that did not receive surgery, we examined the possible contribution of this 
receptor in mounting the angiogenic response.  An adoptive transfer of CX3CR1-/- 
monocytes showed a modest, but significant, decrease in revascularization compared 
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to CX3CR1-sufficient controls (Figure 2.5).  Further studies will be necessary to 
determine if this defect in revascularization is due to a decreased ability of CX3CR1-/- 
cells to home to the ischemic lesion, to attach to damaged endothelium via the 
CX3CR1/CX3CL1 interaction, or to survive at the inflammatory site.   
As the loss of CX3CR1 only appeared to have a minor effect on the 
revascularization potential of monocytes, we looked for other ways in which non-
ischemic donor monocytes may have such a profound impact on the revascularization 
of ischemic recipients.  To accomplish this, an unbiased screen for 58 unique soluble 
factors was performed on adductor muscle supernatant from mice undergoing HLI 
with and without an adoptive transfer.  Interestingly, the potently angiogenic factors 
VEGF, MCP-1, and MMP-9 were all found to be upregulated post-adoptive transfer.  
The role of VEGF in recruiting macrophages which contribute to angiogenesis has 
been extensively described.  For example a host of experiments using neutralizing 
antibodies or soluble receptors demonstrated that VEGF is a major contributor to 
post-ischemic as well as tumor angiogenesis (Cursifen, 2004; Frank, 1995; Adamis, 
1996).  Based upon the critical role of this factor in angiogenesis, the increased 
production of VEGF observed upon adoptive transfer likely is a large contributor to 
the accelerated angiogenesis observed in our model.    
Like VEGF, MCP-1 is likewise a well-known regulator of angiogenesis.  
MCP-1 is secreted from monocyte/macrophages, smooth muscle cells, and endothelial 
cells within ischemic tissue (Goede, 1999; Lakshminarayanan, 2001).  In addition, 
MCP-1 has been shown to directly induce VEGFA expression from endothelial cells 
(Hong, 2005).  The addition of recombinant MCP-1 or its overexpression by gene 
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transfer has been shown to significantly enhance revascularization in ischemic tissues 
which is associated with increased macrophage recruitment (Ito, 1997; Muhs, 2004; 
Schwarz, 2004).  MCP-1–/– mice had impaired monocyte recruitment and blood flow 
recovery after hindlimb ischemia, which could be reversed by local treatment with 
purified MCP-1 protein (Vosukil, 2004).   
MMP-9 belongs to a family of zinc-containing endopeptidases which play a 
role in vascular remodeling by degrading the extracellular matrix (Heissig, 2003).  
MMP-9 has been shown to mobilize endothelial progenitor cells (EPCs) from the 
bone marrow niche (Hessig, 2002) and to recruit bone marrow-derived leukocytes to 
tumors (Jodele, 2005).  Secretion of MMP-9 by tumor associated macrophages 
(TAMs) is a major signal governing tumor angiogenesis in several models (Coussens, 
2004; Giraudo, 2004; Dirkx, 2006).  The increased levels of MMP-9 observed post-
adoptive transfer demonstrate that in addition to its importance in tumor models, this 
proteinase likewise plays a critical role in repairing post-ischemic injury.  
Apolipoprotein A1 (ApoA1) is the major protein component of the high 
density lipoprotein (HDL) complex.  While largely described as an anti-inflammatory 
regulator, recent evidence suggests that ApoA1 may exhibit anti-inflammatory 
functions at the steady state but pro-inflammatory functions under conditions of 
systemic inflammation (Navab, 2005).  In our model of hindlimb ischemia, ApoA1 is 
clearly protective as markedly increased levels are observed post-adoptive transfer 
and an adoptive transfer of ApoA1-/- monocytes does not improve revascularization.  
Interestingly, ApoA1 is known to be secreted by hepatocytes and some cells of the 
small intestine, and its production by macrophages has not been previously described.  
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Further studies will be required to determine if monocyte/macrophages do, in fact, 
secrete ApoA1, or if alternatively, macrophage development in an ApoA1-deficient 
setting leads to phenotypic changes which limits their pro-angiogenic capacity.   
 Taken together, these data identify a specific subset of monocytes which 
potently enhances angiogenesis in an adoptive transfer setting and describe several 
factors which are significantly increased in association with this adoptive transfer.  
Future studies will be required to delineate the specific mechanism by which an 
adoptive transfer of a small proportion of monocytes leads to significantly increased 
blood flow recovery.  A better understanding of this process may unveil promising 
therapeutic strategies for a variety of ischemic disorders.  
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Figure 2.1   
Adoptively transferred donor monocytes home to the site of ischemia and a 
concomitant recruitment of additional endogenous monocytes is observed.  Ficoll-
purified BM-MNCs were harvested from nonischemic donor mice, labeled with 
CFSE, and 2x106 cells were adoptively transferred into ischemic recipients at 24 
hours post-HLI.  The ischemic adductor muscle was harvested at the times indicated, 
subjected to collagenase digestion and homogenization, and analyzed by flow 
cytometry.  The absolute number of CFSE+F4/80+ donor monocytes (A), CFSE-
F4/80+ endogenous monocytes (B), CFSE+Gr-1hi donor neutrophils (C), and CFSE-
Gr-1hi endogenous neutrophils (D) was determined by multiplying the percentages of 
cells obtained by flow cytometry by hemacytometer counts of whole adductor 
muscle.   
 
Figure 2.2 
An adoptive transfer of the inflammatory, but not resident, subset of monocytes 
significantly improves revascularization post-HLI.  Monocytes of the CX3CR1loGr-1+ 
inflammatory and CX3CR1hiGr-1- resident subsets were sort-purified from 
CX3CR1+/GFP mice. 2x105 sorted monocytes were adoptively transferred via a tail 
vein injection into ischemic recipients at 24 hours post-HLI.  The blood flow ratio of 
the ischemic versus nonischemic leg was assessed using laser Doppler imaging over a 
14 day time course.   
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Figure 2.3.   
The inflammatory subset of monocytes is selectively mobilized from the bone marrow 
into the blood post-HLI.  Hindlimb ischemia surgeries were performed in CX3CR1 
GFP/+
 mice and peripheral blood (A) and bone marrow (B) were harvested at the times 
indicated.  Percentages of the inflammatory (GFPloGr-1+) or resident (GFPhiGr-1-) 
subsets were identified by flow cytometry and multiplied by the total white blood 
count in order to determine the absolute number of monocytes present.   
 
Figure 2.4 
Monocytes of the inflammatory subset accumulate at the ischemic lesion post-HLI.  
CX3CR1GFP/+ mice were subjected to hindlimb ischemia and the ischemic adductor 
muscles were harvested at the indicated time points.  Muscles were homogenized and 
the total number of inflammatory (GFPloGr-1+) and resident (GFPloGr-1-) monocytes 
were quantified using percentages obtained using flow cytometry multiplied by 
absolute cell numbers obtained by hemacytometer counts (n=3-5).   
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Figure 2.5   
 
Expression of CX3CR1 is decreased upon induction of ischemia and CX3CR1-/- 
monocytes demonstrate a reduced capacity to stimulate angiogenesis.  (A)  Whole 
bone marrow was prepared from CX3CR1+/GFP mice at baseline or at 24 hours post-
HLI.  Cells were stained for Gr-1 and analyzed using flow cytometry.  (B)  The 
CX3CR1loGr-1+ inflammatory monocyte subset was sort purified from the bone 
marrow of a CX3CR1-/- donor and 2x105 cells were adoptively transferred into 
ischemic recipients at 24 hours post-HLI.  Mice were analyzed using laser Doppler 
scanning over a 14-day time course.   
 
 
Figure 2.6.   
Local production of VEGF, MCP-1, MMP-9, and apolipoprotein A1 is increased 
post-adoptive transfer.  Ischemic adductor muscles from ischemic mice with (dashed 
bars) or without (solid bars) an adoptive transfer of 2x106 BM-MNCs were 
harvested.  Muscles were treated with collagenase and homogenized as described in 
Methods and the cell free supernatant was obtained.  Cell free muscle supernatants 
were subjected to a multiplex ELISA-based screen for 58 unique soluble factors.  
Levels of VEGF (A), MCP-1 (B), MMP-9 (C) and apolipoprotein A1 (D) were 
upregulated locally in mice receiving adoptive transfer.  (n=1-2 pooled samples, 
representing 3-6 mice, respectively).   
  
49
Figure 2.7 
An adoptive transfer of apolipoprotein A1-deficient monocytes does not improve 
revascularization post-HLI  The inflammatory subset of monocytes was sorted from 
ApoA1-/- mice based on CD115+Gr-1+ expression.  2x105 of these sorted cells were 
adoptively transferred into ischemic recipients at 24 hours post-HLI.  The blood flow 
ratio of the ischemic versus nonischemic leg was assessed over a 14 day time course 
using laser Doppler imaging.   
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Figure 2.1 
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Figure 2.2 
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Figure 2.3 
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Figure 2.4   
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Figure 2.5 
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Figure 2.6 
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Figure 2.7 
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Chapter 3 
 
Systemic Signals Generated by Interleukin-6 (IL-6) and 
Granulocyte-Colony Stimulating Factor (G-CSF) 
Influence the Angiogenic Capacity of Bone Marrow 
Resident Monocytes  
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3.1  ABSTRACT 
There is considerable interest in the potential of cell-based approaches to mediate 
therapeutic angiogenesis for acute and chronic vascular syndromes. Using a mouse 
model of hindlimb ischemia, we previously showed that adoptive transfer of a small 
number of donor monocytes significantly enhanced revascularization. Herein, we 
provide data suggesting the bone marrow resident monocytes sense systemic signals 
that influence their future functional capacity.  Specifically, following induction of 
distant ischemia, the angiogenic capacity of bone marrow resident monocytes is 
markedly reduced.  We provide evidence that granulocyte-colony stimulating factor 
(G-CSF) and interleukin-6 (IL-6) represent such “conditioning” signals.  Systemic 
levels of G-CSF and IL-6 are significantly increased following induction of hindlimb 
ischemia.  Accordingly, bone marrow resident monocytes from ischemic mice 
exhibited increased STAT3 phosphorylation and STAT3 target gene expression.  
Finally, G-CSF receptor-/- and IL-6-/- mice were resistant to the deleterious effects of 
ischemic conditioning on monocyte angiogenic potential.  RNA expression profiling 
suggested that ischemia-conditioned monocytes in the bone marrow are polarized 
towards expression of M2-associated genes.  Consistent with this observation, M2-
skewed monocytes from SHIP-/- mice also had impaired angiogenic capacity.   
Collectively, these data show that G-CSF and IL-6 provide signals that determine the 
angiogenic potential of bone marrow resident monocytes.   
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3.2  INTRODUCTION 
The bone marrow represents a rich reservoir of cells that are able to stimulate 
angiogenesis.  Delivery of bone marrow cells to sites of ischemia, either by direct 
injection into ischemic tissue (1) or by mobilization of bone marrow cells into the 
blood (2), has been shown to stimulate angiogenesis in animal models.  Moreover, 
several clinical trials have utilized direct injection of bone marrow cells to stimulate 
revascularization.  Though preliminary, there is evidence that this approach may have 
modest clinical benefit in patients with acute myocardial infarction (3) or peripheral 
vascular disease (4).  Importantly, the bone marrow is comprised of many cell types, 
and the cell population(s) that stimulate angiogenesis have not been fully defined.  
The identification of the relevant cell populations and a better understanding of the 
signals that regulate their angiogenic activity may lead to improved strategies for cell-
based therapeutic angiogenesis. 
Within the bone marrow, cell populations with known angiogenic activity 
include monocytes, endothelial cells and natural killer cells (5).  Accumulating 
evidence suggests that monocytes may be the key bone marrow cell type mediating 
angiogenesis upon delivery to sites of ischemia.  Mice subjected to ischemia exhibit a 
marked endogenous monocytic response, consisting of increased production in the 
bone marrow and trafficking to the lesion (6).  Monocytes are thought to stimulate 
angiogenesis through secretion of angiogenic growth factors, degradation of 
extracellular matrix by the release of proteases, and increases in vascular permeability 
by the deposition of fibrin.  Accordingly, ablation of macrophages is associated with 
a significant reduction in post-ischemic angiogenesis (7-9).  Conversely, we recently 
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showed that early delivery of bone marrow monocytes to sites of ischemia markedly 
enhanced reperfusion in a murine model of acute hindlimb ischemia (6). 
 The cytokines granulocyte-colony stimulating factor (G-CSF) and interleukin-
6 (IL-6) are known to provide important survival and activation signals to 
monocyte/macrophages, acting through signal transducer and activator of 
transcription 3 (STAT3) signaling intermediates (10).  IL-6 and G-CSF are induced in 
several ischemic settings including a murine model of ischemic acute kidney injury 
(11) and a rat model of gut ischemia/reperfusion (12).  Likewise, levels of these 
cytokines have been shown to be elevated in a variety of ischemic disorders in 
patients, including severe heart failure patients (13, 14) and vascular surgery-
associated ischemia (15).  The effect of these cytokines on the bone marrow 
compartment has not previously been investigated. 
 Herein, we demonstrate that the addition of only a small proportion of 
adoptively transferred monocytes from a non-ischemic donor significantly enhances 
revascularization post-hindlimb ischemia (HLI).  Based on this finding we set out to 
assess differences in proangiogenic capacity between endogenous ischemia-
conditioned monocytes and donor basal monocytes.  We demonstrate that ischemia-
conditioned monocytes are unable to enhance revascularization post-HLI and that this 
defect is dependent upon signaling by G-CSF and IL-6.  Additionally, bone marrow 
resident monocytes subjected to ischemic signals exhibit reduced expression of 
classical M1 genes and increased expression of M2 genes.  Accordingly, an adoptive 
transfer of M2-skewed monocytes obtained from Src homology 2 domain-containing 
inositol 5'-phosphatase 1-/- (SHIP-/-) mice does not improve blood flow recovery 
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post-HLI.  This study provides the first evidence that systemic signals generated by 
ischemia can lead to functional alterations in bone marrow resident monocytes and 
has important implications for cell-based therapeutic angiogenesis approaches. 
 
3.3  MATERIALS AND METHODS 
 
Mice.  IL-6-/- on a C57BL/6 background were obtained from The Jackson Laboratory 
(Bar Harbor, ME).  CX3CR1GFP/+ mice on a C57BL/6 background were a generous 
gift from Dr. Dan Littman (Skirball Institute of Biomolecular Medicine, New York 
School of Medicine, New York, NY).  SHIP-/- mice on a C57BL/6 background were a 
generous gift from Dr. F. Patrick Ross (Washington University School of Medicine, 
St. Louis, MO)   G-CSFR-/- mice on a C57BL/6 background were generated as 
previously described (43).  Mice were housed in a specific pathogen-free 
environment.  The Washington University Animal Studies Committee (St. Louis, 
MO) approved all experiments.   
 
Murine hindlimb ischemia model.  Mice were anesthetized by an intraperitoneal 
injection of a solution of 87 mg/kg ketamine; 13 mg/kg xylazine.  An incision was 
made at the mid-portion of the right hindlimb proximal to the femoral artery and the 
femoral artery and vein were dissected free from the nerve.  The proximal portion of 
the femoral artery and vein were ligated with Perma-Hand taper point (6-0) 
nonabsorbable silk surgical sutures (Ethicon, Summerville, NJ).  The distal portion of 
the saphenous artery and vein and remaining arterial and venous side branches were 
  
66
ligated and then excised from the hindlimb.  The incision was then closed using 
Nexaband veterinary glue (Abbott Animal Health, Abbott Park, IL).   
 
Laser Doppler perfusion imaging.  Blood perfusion in the hindlimb was monitored 
by laser Doppler imaging (MoorLDI-2, Moor Instruments, UK).  Prior to imaging, 
mice were anesthetized with ketamine/xylazine, and placed on a heating plate at 37oC 
for 10 minutes in order to minimize temperature variations.  The laser Doppler image 
was analyzed by averaging the perfusion, expressed as the relative unit of flux as 
determined by Moor Instruments, over the surface of the ischemic and non-ischemic 
foot.  To control for ambient light and temperature, calculated perfusion was 
expressed as the flux ratio between the ischemic and non-ischemic limbs. 
 
Isolation and adoptive transfer of bone marrow mononuclear cells (BM-MNCs) 
or purified monocytes.   Bone marrow was harvested from the femurs of donor mice 
and mononuclear cells were isolated by centrifugation across a 1.011 density gradient 
(Histopaque, Sigma-Aldrich, St. Louis, MO) at 1700xg for 30 minutes.  Pure 
monocyte populations were obtained from CX3CR1GFP/+ mice using a MoFlo high 
speed cell sorter (Dako, Fort Collins, CO) based on CX3CR1loGr-1+ expression or 
CD115+Gr-1+ expression in mice which do not express CX3CR1-GFP.  2x106 BM-
MNCs or 2x105 purified monocytes were administered intravenously into recipient 
mice 24 hours after the induction of hindlimb ischemia.  For trafficking experiments, 
cells were incubated with 2.5uM carboxyfluorescein succinimidyl ester (CFSE) 
  
67
(Invitrogen, Eugene, OR) in PBS for 10 minutes at 37oC prior to intravenous 
injection.  
 
Homogenization of muscle tissue.  The adductor muscle was dissected free of the 
ischemic hindlimb, subjected to mechanical disruption, and incubated 3 mg/mL 
collagenase type I (Worthington Biochemical, Lakewood, NJ) for one hour on a 37° 
shaking incubator.  Cells were further homogenized by drawing through a 18-gauge 
and 22-gauge needle and then filtered through a 50 uM cell filter (Partec, Mt. Laurel, 
NJ).  The resulting suspension was spun at 8000xg for 5 minutes, and the cell-free 
supernatant analyzed by ELISA. 
 
Histological analyses.  Ischemic adductor muscles were excised and fixed overnight 
in 10% formalin.  Tissue was then paraffin-embedded, sectioned, and stained with 
hematoxylin/eosin (H&E).  The number of newly regenerated myofibrils containing 
centrally-localized nuclei was scored by counting 100 cells in three distinct fields of 
each section (300 total myofibrils scored).  Leukocyte infiltration present in the entire 
section area was given a histological score as follows: 1=0-25% affected area; 2=25-
50% affected area; 3=50-75% affected area; 4=75-100% affected area; n=3, p<0.05.  
All scoring was conducted in a blinded fashion by two independent investigators.   
 
Unbiased screen for secreted factors.  Cell free supernatants were obtained from 
homogenized adductor muscle as described above.  Supernatants were analyzed using 
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the RodentMap v2.0 multiplex analysis for 58 unique soluble factors (Rules Based 
Medicine, Austin, TX). 
 
ELISA.  ELISA analysis for G-CSF and IL-6 (R&D Systems, Minneapolis, MN) 
were performed according to manufacturer’s instructions. 
 
Flow cytometry.  Cells were incubated with the indicated primary antibody for 1 
hour at 4°C in PBS containing 0.2% BSA and 0.1% sodium azide. The following 
primary antibodies were used: Gr-1, B220, CD3, F4/80, CD115 (eBioscience, San 
Diego, CA).  Cells were analyzed on a FACScan flow cytometer (BD Bioscience, San 
Jose, CA). 
 
Flow cytometric phosphorylation assay.  Femurs obtained from ischemic or non-
ischemic CX3CR1GFP/+ transgenic mice were flushed with PBS containing 0.2% 
bovine serum albumin (BSA).  Cells were immediately fixed and permeabilized using 
BD Cytofix/Cytoperm reagent according to manufacturer’s instructions (BD 
Biosciences, San Jose, CA).  Permeabilized cells were stained using BD Phosflow 
anti-STAT3 or anti-STAT5 antibodies (BD Biosciences).  Cells were then gated on 
the CX3CR1lo inflammatory monocyte population and the mean fluorescent intensity 
measured. 
 
Microarray analysis.  CX3CR1-GFPloGr-1+ inflammatory monocytes were sorted 
from the bone marrow of CX3CR1GFP/+ transgenic mice, with our without hindlimb 
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ischemia, directly into Trizol (Invitrogen, Carlsbad, CA).  Three independent 
replicates were performed.  Total RNA was prepared according to manufacturer’s 
instructions, amplified, labeled, and hybridized to a MouseRef-6 BeadChip (Illumina, 
San Diego, CA, USA).  Expression profiles from basal inflammatory monocytes were 
compared to those of ischemia-conditioned monocytes using the Spotfire analysis 
program (TIBCO, Somerville, MA, USA). After normalization, mean signal 
intensities for each probeset were calculated across the three experiments. Probesets 
upregulated or downregulated in ischemia-conditioned monocytes versus basal 
monocytes were selected based upon the following selection criteria: (i) mean signal 
intensity > 40 in at least two of three probesets corresponding to the upregulated 
condition; (ii) greater than threefold changes in mean signal intensity (hereafter 
referred to as “fold-induction ratio”). (iii) Statistical significance (P < 0.03) by t-
test/Anova.  In cases where multiple probesets corresponded to the same gene, the 
probeset with the highest average signal intensity and greatest number of present calls 
was used. 
 
Statistics.  Statistical significance between curves in time courses was determined by 
two-way ANOVA with Bonferroni post-testing.  Unpaired students’ t-test was 
performed on single observation data.  Significance was determined as p<0.05.    
 
 
3.4  RESULTS 
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3.4.1  Adoptive transfer of bone marrow monocytes significantly improves 
revascularization in mice after induction of hindlimb ischemia 
Monocytes were sort-purified from the bone marrow of donor mice, labeled 
with carboxyfluorescein succinimidyl ester (CFSE), and adoptively transferred into 
recipient mice 24 hours after surgical induction of unilateral hindlimb ischemia.  
Consistent with a previous report by our laboratory (6), infusion of as few as 2 x 105 
bone marrow monocytes significantly enhances blood flow recovery as assessed by 
laser Doppler analysis (Figure 1A).  The number of donor (CSFE+) and recipient 
(CSFE-) monocytes recruited to the ischemic adductor muscle was assessed by flow 
cytometry (Figure 1B-C).  Interestingly, though donor monocytes clearly home to and 
are retained in the ischemic tissue, they make up only a small fraction (0.1% to 1%) 
of the total monocytes/macrophages present in the lesion.  Moreover, in control mice 
not receiving donor monocytes, blood flow recovery was significantly delayed 
despite the recruitment of a large number of CFSE- host monocytes (Figure 1B-C).  
Together, these data suggest dramatic differences in the ability of donor versus host 
monocytes to stimulate revascularization.  
 
3.4.2  Adoptive transfer of BM-MNCs from ischemic donors does not improve 
revascularization after induction of hindlimb ischemia 
Local ischemia/inflammation can induce systemic production of cytokines, 
such as IL-6, G-CSF, tumor necrosis factor-alpha (TNF-α), interferon-gamma (IFN-
γ), and transforming growth factor-beta (TGF-β), that regulate immune cell function 
(16).  We hypothesized that systemic factors induced by hindlimb ischemia may alter 
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the ability of bone marrow resident monocytes to stimulate angiogenesis.  To test this 
hypothesis, we harvested BM-MNCs from mice 24 hours after induction of hindlimb 
ischemia.  Of note, cells were obtained only from the non-ischemic hindlimb of the 
ischemic donor, as cells present in the femur of the ischemic hindlimb are subject to 
local effects of hypoxia and inflammation (Figure 2A).  In this study, we refer to 
these cells as ischemia-conditioned BM-MNCs and cells from non-ischemic mice as 
basal BM-MNCs.  Basal or ischemia-conditioned BM-MNCs were adoptively 
transferred into recipient mice 24 hours after induction of hindlimb ischemia and 
revascularization assessed by laser Doppler imaging (Figure 2B).  In contrast to basal 
cells, ischemia-conditioned BM-MNCs did not improve blood flow recovery (Figure 
2B).   
 Accelerated restoration of blood flow should result in improved tissue 
preservation.  To assess the integrity of muscle tissue post-ischemia, we examined 
histological sections of ischemic adductor muscle 21 days after induction of HLI 
(Figure C-E).  Adoptive transfer of basal bone marrow cells resulted in a significant 
increase in myofibrils with centrally-located nuclei (Figure 2D), a feature associated 
with regenerating myofibrils (17).  In contrast, muscle sections obtained from mice 
receiving ischemia-conditioned BM-MNCs had reduced myofiber regeneration, as 
measured by this assay (Figure 2D).  Interestingly, however, an adoptive transfer of 
either basal or ischemia-conditioned BM-MNC significantly reduced leukocyte 
infiltration present in the ischemic lesion (Figure 2E).  Collectively, these data 
suggest that the tissue reparative capacity of ischemia-conditioned BM-MNCs is 
reduced compared with basal BM-MNCs. 
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3.4.3  Ischemia conditioned bone marrow monocytes demonstrate a reduced 
capacity to stimulate revascularization 
The inability of ischemia-conditioned bone marrow cells to improve blood 
flow recovery may be due directly to a reduction in their ability to stimulate 
angiogenesis or may be secondary to the loss of angiogenic cells from the bone 
marrow.  We have previously used sort-fractionation experiments to show that 
monocytes of the CX3CR1loGr-1+ inflammatory subset represent the angiogenic cell 
type within the BM-MNC fraction (6).  In order to assess if this pro-angiogenic 
population is, in fact, reduced, we quantified the number of inflammatory monocytes 
in the bone marrow 24 hours after induction of ischemia in the contralateral limb.  
Compared with baseline bone marrow, no differences in the percentage or absolute 
number of inflammatory monocytes in the ischemia-conditioned bone marrow were 
observed (Figure 3A & B).   We next asked whether ischemic conditioning leads to a 
defect in monocyte-promoted angiogenesis on a per cell basis.  Inflammatory 
monocytes were sorted from the bone marrow of mice at baseline or at 24 hours after 
induction of hindlimb ischemia and adoptively transferred into ischemic recipients.  
Consistent with our previous data, adoptive transfer of basal inflammatory monocytes 
was associated with significant improvement in blood flow recovery (Figure 3C).  In 
contrast, adoptive transfer of ischemia-conditioned inflammatory monocytes had no 
effect on blood flow recovery (Figure 3C).  These data suggest that ischemia-
conditioned bone marrow resident monocytes have reduced capacity to stimulate 
revascularization.   
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3.4.4  Ischemia-conditioned monocytes home to sites of ischemia normally  
We next assessed whether ischemia-conditioned monocytes are competent to 
home to sites of ischemia.  Basal or ischemia-conditioned bone marrow monocytes 
were labeled with CSFE and adoptively transferred into recipient mice 24 hours after 
induction of hindlimb ischemia.  The magnitude and kinetics of the accumulation of 
ischemia-conditioned monocytes in the ischemic muscle was similar to basal 
monocytes (Figure 4), suggesting that homing of ischemia-conditioned monocytes 
was normal.  
In addition, there was no significant difference in the number of recipient (CFSE-) 
monocytes, neutrophils, T cells, or B cells that infiltrated the ischemic tissue (data not 
shown).  
 
3.4.5  Ischemia-conditioned bone marrow resident monocytes have increased 
STAT3 but not STAT5 activation. 
To begin to elucidate the molecular mechanisms responsible for the reduced 
angiogenic capacity of ischemia-conditioned monocytes, we sorted basal or ischemia-
conditioned monocytes from the bone marrow and performed RNA expression 
profiling. Data from three independent experiments were pooled; genes that were 
consistently upregulated or downregulated in ischemia-conditioned monocytes are 
summarized in Supplemental Tables 1 and 2.  Since several well known STAT3 
target genes were found to be significantly upregulated in ischemia-conditioned 
monocytes, including SOCS3, we next assessed STAT3 activation in these cells.  
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Bone marrow cells were harvested from mice at baseline or 24 hours after induction 
of hindlimb ischemia and STAT3 and STAT5 phosphorylation in monocytes assessed 
using a phospho-flow assay in which CX3CR1lo inflammatory monocytes were gated 
(Figure 5A) and mean fluorescence intensity of pSTAT3 or pSTAT5 was assessed 
(Figure 5B).  Compared with basal monocytes, a modest but significant increase in 
STAT3 phosphorylation in ischemia-conditioned monocytes was observed (Figure 
5C).  In contrast, no difference in STAT5 phosphorylation levels was observed 
(Figure 5C) suggesting specific induction of the STAT3 pathway post-ischemia.   
 
 
3.4.6  The impaired angiogenic capacity of ischemia-conditioned monocytes is 
dependent on IL-6 and G-CSF signals  
Localized ischemia can lead to the production of inflammatory cytokines that 
might contribute to STAT3 activation in bone marrow resident monocytes.  To 
address this possibility, we performed an unbiased screen for 58 biomarkers, 
including many cytokines and chemokines, in the serum of mice at baseline or 24 
hours after induction of hindlimb ischemia.  Interestingly, the only factor which was 
significantly elevated from baseline was IL-6 (data not shown).  ELISA confirmed 
increased IL-6 levels (Figure 6A).  We also assayed for G-CSF by ELISA, as G-CSF 
likewise activates STAT3 in monocytes (18), and which was not included in the 
unbiased screen.  Like IL-6, this cytokine was significantly upregulated in the serum 
of ischemic mice (Figure 6B).     
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We next asked if the signals generated by G-CSF and IL-6 are responsible for 
the impaired ability of ischemia-conditioned monocytes to improve revascularization.  
To test this possibility, we assessed the angiogenic capacity of monocytes harvested 
from the bone marrow of IL-6-/- or G-CSFR-/- mice at baseline or 24 hours after 
induction of hindlimb ischemia.  Similar to wild type mice, induction of contralateral 
ischemia did not alter the number or percentage of monocytes in the bone marrow of 
IL-6-/- or G-CSFR-/- mice (data not shown).  Remarkably, ischemic conditioning of 
IL-6-/- or G-CSFR-/- monocytes had no affect on their ability to promote 
revascularization (Figure 6C & D).  These data suggest that signaling by G-CSF and 
IL-6 in bone marrow monocytes is a key determinant of their ability to stimulate 
revascularization.  
 
3.4.7  Ischemia-conditioned monocytes demonstrate a shift towards the 
expression of M2 genes and M2-skewed SHIP-/- monocytes do not improve blood 
flow recovery 
 In response to local environmental signals, tissue macrophages may be 
polarized into two broad activation states: classical (M1) and alternative (M2).  
Classically activated macrophages are induced by proinflammatory signals such as 
IFN-γ and have enhanced cytotoxic and anti-microbial activities.  In contrast, 
alternative activated macrophages are polarized towards tissue repair and 
angiogenesis (19).  Though this classification has been designated based on tissue 
macrophages, we asked whether bone marrow resident monocytes were undergoing 
similar polarization following induction of distant ischemia.  Specifically, we 
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analyzed the RNA profiling data from basal and ischemia conditioned bone marrow 
monocytes for expression of a curated list of well-defined M1- or M2-associated 
genes (Supplemental Table 3 & 4) (20-22).  Expression of the majority of the M1-
associated genes was similar, with the exception of 3 genes that were significantly 
reduced in ischemia-conditioned monocytes (Figure 7A).  Conversely, 7 of 32 M2-
associated genes were increased in ischemia conditioned bone marrow monocytes 
(Figure 7B).  Thus, the RNA expression pattern is suggestive of at least partial 
polarization towards alternative (M2) activation. 
Alternative activation of macrophages is classically associated with tissue 
reparation and angiogenesis, not the decreased repair that was observed with 
ischemia-conditioned (M2-polarized) monocytes.  Thus, we assessed the capacity of 
monocytes from SHIP-/- mice to stimulate revascularization in the hindlimb ischemia 
model; macrophages in SHIP-/- mice are reported to be preferentially polarized 
towards M2 activation (23).  Bone marrow monocytes of the inflammatory subset 
were sort-purified from SHIP-/- mice and adoptively transferred into ischemic 
recipients (Figure 7C).  Consistent with our results with ischemia-conditioned 
monocytes, M2-skewed monocytes from SHIP-/- mice had markedly reduced capacity 
to stimulate revascularization in this model.   
 
 
3.5  DISCUSSION 
In this study, we show that bone marrow monocytes harvested from mice with 
distant ischemia have reduced capacity to stimulate angiogenesis upon adoptive 
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transfer. Interestingly, this finding is consistent with a recent study in which BM-
MNCs obtained from patients with chronic ischemic cardiomyopathy were defective 
in improving angiogenesis post-HLI in nude mice (24).  The bone marrow is 
recognized as the major site of monocyte production and provides a reservoir of 
monocytes that can be mobilized into the blood in response to stress (25).  Our data 
suggest that bone marrow resident monocytes also may sense systemic signals that 
influence their future functional capacity.  This “conditioning” of monocytes in the 
bone marrow represents another level of regulation of monocyte activation.   
We show that in the hindlimb ischemia model, G-CSF and IL-6 provide such 
“conditioning” signals to bone marrow resident monocytes.  Systemic expression of 
G-CSF and IL-6 were significantly increased after induction of hindlimb ischemia, 
reaching levels in the serum that are in seen in other inflammatory conditions (26-28).  
Consistent with G-CSF and IL-6 signaling, a modest but consistent increase in 
STAT3 phosphorylation and induction of several STAT3 target genes was observed 
in ischemia-conditioned bone marrow resident monocytes.  Finally, we show that G-
CSF and IL-6 signaling in monocytes is relevant, since ischemia-conditioned IL-6-/- 
or G-CSFR-/- bone marrow monocytes are able to stimulate revascularization. 
Interestingly, systemic levels of G-CSF and/or IL-6 are increased in many 
inflammatory conditions (29-31), suggesting that these findings may have broad 
relevance for monocyte biology.  
G-CSF has been shown to improve tissue recovery in animal models of 
hindlimb ischemia (2), myocardial infarction (32), focal cerebral ischemia injuries 
(33, 34), and renal ischemia-reperfusion (35, 36).  Moreover, clinical trials utilizing 
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G-CSF to mobilize cells for adoptive transfer have demonstrated efficacy in the 
treatment of peripheral arterial disease in humans (4).  While at first glance, these 
studies would seem at odds with the current findings that G-CSF inhibits the 
angiogenic capacity of monocytes, G-CSF also is a potent mobilizer of monocytes, 
endothelial progenitors, and other cells with potential angiogenesis-promoting 
activity.  Thus, the increased delivery of these cells to sites of ischemia/tissue injury 
may overcome the negative effect that G-CSF signaling has on the function of 
recruited monocytes.  On the other hand, trials of stem cell/leukocyte mobilization by 
G-CSF after myocardial infarction in humans have been disappointing (37).  It is 
possible that monocytes mobilized by alternative agents, such as AMD3100, may 
have better efficacy. 
  Macrophages are known to polarize along the classical M1 activation 
pathway or conversely to exhibit an M2 alternative activation phenotype, however 
emerging data suggest that macrophage activation is quite heterogeneous and that 
these classifications may, in fact, be oversimplified.  M1 macrophages are generated 
in response to infectious or inflammatory stimuli and function to clear intracellular 
pathogens and also play a role in tumor resistance.  In contrast, M2 macrophages are 
elicited in response to IL-4 and IL-13 (M2a subset) or IL-10 (M2c subset) signaling 
and exhibit diverse functions including immunity to extracellular parasites, the 
evolution of an allergic response, matrix remodeling, and tumor promotion (38).  M2 
macrophages have been associated with angiogenesis in vitro (39) and in a wide 
variety of tumor models (40).  The role that the M2 macrophage subset plays in post-
ischemic angiogenesis, however, has not previously been examined.   
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The M1 and M2 classification of macrophage activation is based on data from 
tissue macrophages.  Thus, its relevance to monocyte activation in blood or bone 
marrow is unclear.  With this caveat in mind, our RNA profiling data suggest that 
ischemia-conditioned bone marrow monocytes are polarized towards a M2 
phenotype.  Expression of hallmark M2 genes, Arg1 and Ym1, is increased, while a 
trend of decreased expression of several M1-asscoicated genes was observed in 
ischemia-conditioned bone marrow monocytes (Supplemental Tables 3 & 4).  At first 
glance, these results may be counter-intuitive, since M2 activation is associated with 
enhanced angiogenesis and tissue repair and not the impaired angiogenic capacity that 
was observed.  However, these results are consistent with our finding that monocytes 
obtained from SHIP-/- mice, known to exhibit preferential M2 polarization, also do 
not improve blood flow recovery in ischemic recipients.  Likewise, two recent studies 
have demonstrated that mice deficient in IL-10, a critical determinant of M2c 
polarization, have improved blood flow recovery post-HLI compared to wild type 
controls due, at least in part, to the increased levels of VEGF and active matrix 
metalloproteinases in these mice (41, 42).  Though it will require further study, it is 
possible that functions associated with classically activated (M1) macrophages, 
including secretion of proinflammatory cytokines and degradation of extracellular 
matrix, are advantageous early during the course of tissue reparation following acute 
ischemic injury.   
  In summary, our data demonstrate that monocytes derived from an ischemic 
donor have a markedly reduced capacity to improve revascularization compared to 
non-ischemic controls.  We demonstrate that G-CSF and IL-6 are generated upon 
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induction of ischemia and that signaling by these cytokines plays an essential role in 
altering the phenotype of bone marrow-resident monocytes, including the induction 
of STAT3 target genes and increased expression of well-defined M2-associated 
genes.  These data provide the first evidence that systemic inflammatory signals lead 
to significant functional changes in bone marrow-resident monocytes.  A specific 
delineation of the ways in which inflammation- and ischemia-driven signals impact 
the angiogenic capacity of bone marrow-resident monocytes may have important 
implications for the treatment of a variety of ischemic disorders.  
  
 
 
 
3.6  FIGURE AND FIGURE LEGENDS 
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Figure 1.  The addition of a small proportion of macrophages obtained from an 
non-ischemic donor significantly improves revascularization post-hindlimb 
ischemia.  (A) Monocytes were sort-purified from non-ischemic donors, labeled with 
CFSE and adoptively transferred into ischemic recipients at 24 hours post-HLI.  
Revascularization of recipients was assessed over 14 days using laser Doppler 
imaging.  (B) F4/80+ macrophages present in homogenized, ischemic adductor 
muscle tissue were gated and assessed for CFSE expression as shown in this 
representative histogram plot.  (C) The ratio of (CFSE+ donor)/(CFSE- endogenous) 
F4/80+ macrophages is shown at several time points post-adoptive transfer (n=3 at 4 
and 72 hours; n=10 at 48 hours).  Data represent mean ± SEM.   
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Figure 2.  An adoptive transfer of BM-MNCs obtained from an ischemic donor 
does not improve revascularization post-HLI.  (A) BM-MNCs were obtained from 
the non-ischemic limb of a 24-hour post-HLI donor using Ficoll purification and 
injected intravenously into an ischemic recipient at 24 hours post-HLI according to 
the scheme illustrated.  (B) Blood flow recovery in recipient mice was assessed by 
laser Doppler imaging over a 14-day time course; n=6.  (C) Ischemic adductor 
muscles were obtained at 21 days post-HLI and were sectioned and stained with 
H&E.  Original magnification x 40.  (D) The percentage of newly regenerated 
myofibrils containing centrally-localized nuclei, indicated in panel (C) with 
arrowheads, was scored by counting 300 cells in three distinct fields of each section; 
n=3, p<0.05.  (E) Leukocyte infiltration present in the entire section area was given a 
histological score as follows: 1=0-25% affected area; 2=25-50% affected area; 3=50-
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75% affected area; 4=75-100% affected area; n=3 p<0.05.  Data represent the mean ± 
SEM. 
 
 
Figure 3.  Ischemia-conditioned monocytes are not competent to mediate 
revascularization.  (A) Bone marrow cells were obtained from CX3CR1GFP/+ mice at 
baseline (upper panel) or at 24 hours post-ischemia (lower panel) and analyzed by 
flow cytometry.  The percentages of CX3CR1loGr-1+ inflammatory monocytes are 
noted.  (B) The absolute number of inflammatory bone marrow monocytes was 
quantified by multiplying the percentage obtained by flow cytometry by the total 
white blood count per femur (n=5).  (C) Laser Doppler analysis of mice receiving 
2x105 sort-purified inflammatory monocytes from non-ischemic donors (squares, 
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dashed line) or ischemia-conditioned donors (circles, solid line).  Data represent the 
mean ± SEM, p<0.05.   
 
 
 
 
 
 
Figure 4.  Adoptively transferred ischemia-conditioned monocytes are competent to 
home to ischemic tissue.  BM-MNCs were harvested from wild type or 24 hour-post 
HLI donors, labeled with CFSE, and intravenously adoptively transferred into 
ischemic recipients.  At the time points indicated, the absolute number of CFSE+ 
donor macrophages present in the ischemic adductor muscle was quantified using cell 
percentages obtained by flow cytometry multiplied by the total cell number obtained 
by hemacytometer counts; n=3 at 4 and 48 hours; n=10 at 24 hours.  Data represent 
the mean ± SEM.   
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Figure 5.  Increased STAT3 phosphorylation is observed in ischemia-conditioned 
bone marrow monocytes.  Bone marrow cells were harvested from non-ischemic or 
ischemic mice, immediately subjected to fixation/permeabilization, and stained with a 
phospho-specific anti-STAT3 or anti-STAT5 antibodies for flow cytometric analysis.  
Inflammatory (CX3CR1-GFPlo) monocytes were gated (A) and mean fluorescent 
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intensity of pSTAT3 staining was quantitated (B-C).  Data are n=3, representative of 
four independent experiments.  Data represent the mean ± SEM, p<0.05.   
 
 
 
 
 
 
 
 
 
Figure 6.  IL-6 and G-CSF are produced upon induction of ischemia and loss of 
either of these signals is sufficient to restore the ability of ischemic adoptively 
transferred monocytes to promote angiogenesis.  (A-B) Serum levels of IL-6 (A) and 
G-CSF (B) were assessed at the indicated time points post-HLI.  Asterisks denote a 
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significant change from baseline, n=4-9.  (C-D) Bone marrow monocytes were 
purified using cell sorting from non-ischemic (solid line) or 24-hour ischemic (dotted 
line) wild type, IL-6-/- (C), or G-CSFR-/- (D) donors and 2x105 cells were adoptively 
transferred into ischemic recipients at 24 hours post-HLI.  Revascularization of 
recipients was then assessed for 14 days using laser Doppler imaging.  Data represent 
the mean ± SEM, p<0.05.         
 
 
 
 
 
Figure 7.  Differential M1/M2 gene expression post-ischemic conditioning, and 
reduced revascularization capacity of SHIP-/- M2-skewed monocytes.  
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 (A-B)  CX3CR1loGr-1+ inflammatory bone marrow monocytes were sort-purified 
from mice at baseline or at 24 hours post-HLI and RNA expression profiling 
performed on three independent replicates.   Shown are normalized signals for all 
M1-associated genes (A) or M2-associated genes that displayed consistent changes 
(increased or decreased) from control cells.   (C)  CD115+Gr-1+ monocytes were 
sorted from SHIP+/+ (squares, solid line), SHIP+/- (triangles, dashed line) and SHIP-/- 
(circles, solid line) mice and adoptively transferred into ischemic recipients at 24 
hours post-HLI.  Blood flow recovery was assessed by laser Doppler imaging over a 
14-day time course.  Data represent the mean ± SEM, p<0.05.     
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Supplemental Table 1.  Genes upregulated in ischemia-conditioned bone marrow monocytes 
  
        
Fold- t-test/ 
Gene Symbol Baseline 
Ischemia-
conditioned Change Anova 
serum amyloid A 3 Saa3* 124 + 50 7425 + 1183 59.9 0.00 
interleukin 1 receptor, type II Il1r2 17 + 1 368 + 82 20.6 0.01 
leucine-rich alpha-2-glycoprotein 1 Lrg1 618 + 257 7712 + 1477 12.5 0.01 
suppressor of cytokine signaling 3 Socs3* 137 + 79 1191 + 315 8.7 0.03 
sterol O-acyltransferase 2 Soat2 36 + 6 296 + 54 8.2 0.01 
glycosylphosphatidylinositol specific phospholipase D1  Gpld1 22 + 10 164 + 11 7.2 0.00 
interferon induced transmembrane protein 1 Ifitm1 366 + 54 2334 + 576 6.4 0.03 
chondroitin sulfate proteoglycan 2  Cspg2 48 + 8 290 + 13 6.4 0.01 
potassium channel, subfamily K, member 13 Kcnk13 37 + 4 217 + 38 6.0 0.01 
serine protease inhibitor, Kunitz type 1  Spint1 47 + 2 269 + 72 5.7 0.03 
insulin-like growth factor binding protein 6  Igfbp6 44 + 5 240 + 23 5.5 0.00 
DNA (cytosine-5-)-methyltransferase 3-like Dnmt3l 36 + 12 174 + 19 4.8 0.00 
ribosomal protein S19  Rps19 11 + 3 52 + 8 4.7 0.01 
guanine nucleotide binding protein, beta 5  Gnb5 27 + 7 125 + 8 4.6 0.01 
spermidine synthase  Srm 303 + 173 1054 + 80 3.5 0.03 
a disintegrin and metalloprotease domain 8  Adam8 17 + 7 62 + 7 3.5 0.00 
complement component 1, r subcomponent-like C1rl 193 + 35 610 + 28 3.2 0.02 
heat shock protein 1  Hspd1 159 + 84 488 + 38 3.1 0.02 
cytidine 5-triphosphate synthase Ctps 59 + 28 154 + 15 2.6 0.04 
ribonucleotide reductase M2  Rrm2 107 + 49 266 + 18 2.5 0.04 
The average (+ SEM) raw signal of triplicate experiments is shown.         
Genes denoted with * indicate STAT3 target genes.          
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Supplemental Table 2.  Genes downregulated in ischemia-conditioned bone marrow monocytes 
  
        
Fold- t-test/ 
Gene Symbol Baseline 
Ischemia-
conditioned Change Anova 
ureidopropionase, beta  Upb1 349 + 24 51 + 15 0.152 0.00 
solute carrier family 14 (urea transprorter), member 1 Slc14a1 90 + 24 12 + 2 0.159 0.03 
myxovirus (influenza virus) resistance 2 Mx2 209 + 28 46 + 11 0.217 0.01 
reticulon 1  Rtn1 78 + 14 19 + 12 0.221 0.03 
toll-like receptor 11 Tlr11 68 + 11 15 + 2 0.229 0.01 
2-5 oligoadenylate synthetase-like 2 Oasl2 142 + 33 30 + 3 0.231 0.03 
2-5 oligoadenylate synthetase-like 1 Oasl1 195 + 9 47 + 10 0.241 0.00 
interferon regulatory factor 4 Irf4 303 + 32 73 + 8 0.244 0.00 
similar to Ifi204 protein LOC240921 268 + 58 59 + 10 0.244 0.02 
interferon-induced protein with tetratricopeptide repeats 2 Ifit2 538 + 67 141 + 23 0.260 0.00 
interferon regulatory factor 7 Irf7 670 + 42 175 + 7 0.265 0.00 
PHD finger protein 11  Phf11 454 + 105 116 + 42 0.277 0.04 
angiotensin receptor-like 1 Agtrl1 76 + 9 20 + 2 0.278 0.00 
peptidyl arginine deiminase, type II Padi2 2136 + 227 605 + 22 0.288 0.00 
Otoferlin Otof 212 + 26 59 + 1 0.288 0.00 
interferon activated gene 203 Ifi203 287 + 42 83 + 13 0.290 0.01 
ubiquitin specific protease 18  Usp18 816 + 147 230 + 8 0.295 0.02 
D site albumin promoter binding protein Dbp 179 + 28 52 + 4 0.304 0.01 
angiotensin converting enzyme Ace 218 + 21 70 + 47 0.306 0.04 
keratin complex 2, basic, gene 7  Krt2-7 139 + 16 46 + 10 0.321 0.01 
The average (+ SEM) raw signal of triplicate experiments is shown.         
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Supplemental Table 3.  M1-associated genes 
            
              
M1 Genes which change* upon induction of ischemia:           
              
Gene Symbol   
Baseline 
A 
Ischemia 
A   
Baseline 
B 
Ischemia 
B   
Baseline 
C 
Ischemia 
C   Fold ∆ p-value 
chemokine (C-X-C motif) ligand 9; MIG Cxcl9   133 62   197 47   107 47   0.38 0.03 
chemokine (C-C motif) ligand 3; Mip1alpha Ccl3   1111 395   984 711   106 65   0.56 0.40 
chemokine (C-C motif) ligand 4; Mip1beta Ccl4   522 368   450 332   281 88   0.59 0.24 
tumor necrosis factor Tnf   117 77   167 86   74 55   0.64 0.17 
toll-like receptor 5 Tlr5   120 81   98 71   98 69   0.70 0.02 
toll-like receptor 7 Tlr7   621 344   502 280   535 303   0.56 0.00 
              
M1 Genes unchanged** upon induction of ischemia:           
Gene Symbol   
Baseline 
A 
Ischemia 
A   
Baseline 
B 
Ischemia 
B   
Baseline 
C 
Ischemia 
C   Fold ∆ p-value 
chemokine (C-C motif) ligand 5  Ccl5   88 100   56 20   43 38   0.79 0.75 
CD80 antigen Cd80   315 323   302 281   298 310   1.00 1.00 
CD86 antigen Cd86   751 866   796 721   802 883   1.05 0.50 
Fc receptor, IgG, low affinity III  Fcgr3   5474 4899   3387 4016   3109 3634   1.08 0.83 
Fc receptor, IgG, low affinity Iib Fcgr2b   3180 2525   1903 1816   2557 2241   0.87 0.45 
Fc receptor, IgG, high affinity I Fcgr1   1837 901   795 801   636 617   0.82 0.46 
interleukin 12a Il12a   43 67   36 33   87 48   1.02 0.77 
interleukin 1 beta Il1b   204 177   67 86   103 302   1.69 0.44 
lymphocyte antigen 64  Ly64   69 82   44 37   60 48   0.94 0.90 
toll-like receptor 1 Tlr1   61 57   55 56   74 57   0.90 0.28 
toll-like receptor 2 Tlr2   4135 3730   2323 2365   2373 3339   1.11 0.80 
toll-like receptor 4 Tlr4   313 374   204 365   275 300   1.36 0.10 
toll-like receptor 6  Tlr6   518 507   412 485   401 434   1.08 0.50 
                  
M1 genes not expressed***:              
Gene Symbol   
Baseline 
A 
Ischemia 
A   
Baseline 
B 
Ischemia 
B   
Baseline 
C 
Ischemia 
C   Fold ∆ p-value 
chemokine (C-C motif) receptor 7  Ccr7   9 17   12 14   33 21   N/A N/A 
nitric oxide synthase 2, inducible, macrophage  Nos2   -4 8   8 1   8 4   N/A N/A 
chemokine (C-C motif) ligand 8 Ccl8   10 -2   -5 -2   16 0   N/A N/A 
interferon alpha family, gene 1 Ifna1   12 5   7 21   15 15   N/A N/A 
interferon alpha family, gene B Ifnab   -7 -7   -2 -6   4 -7   N/A N/A 
interleukin 1 receptor, type I  Il1r1   2 23   22 13   18 25   N/A N/A 
chemokine (C-X-C motif) ligand 10 Cxcl10   27 10   35 -3   27 -5   N/A N/A 
chemokine (C-X-C motif) ligand 11 Cxcl11   5 7   2 4   9 2   N/A N/A 
chemokine (C-C motif) ligand 2  Ccl2   43 43   14 11   21 12   N/A N/A 
interleukin 6  Il6   1 1   -2 -3   5 -4   N/A N/A 
*All genes which were expressed at levels greater than 40 relative expression units and which showed consistent      
induction or reduction across all three data sets are reported as "changed."          
**Genes which did not show consistent induction or reduction across all three data sets are reported as "unchanged."    
***Genes with a relative expression value <40 are reported as "not expressed."          
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Supplemental Table 4.  M2-associated 
genes 
             
              
M2 Genes which change* upon induction of 
ischemia:             
Gene Symbol   
Baseline 
A 
Ischemia 
A   
Baseline 
B 
Ischemia 
B   
Baseline 
C 
Ischemia 
C   Fold ∆ 
p-
value 
arginase 1, liver (Arg1) Arg1   -5 490   1 49   1 23   562.00 0.28 
chitinase 3-like 3 (Chi3l3) Chi3l3   407 803   194 422   164 391   2.00 0.14 
interleukin 1 receptor, type II (Il1r2) Il1r2   17 419   20 211   17 475   21.00 0.01 
C-type lectin, superfamily member 9 Clecsf9   425 993   159 542   110 849   34.00 0.03 
leucine-rich alpha-2-glycoprotein 1 Lrg1   1080 9427   566 8880   211 4830   13.00 0.01 
vascular endothelial growth factor A  Vegfa   48 169   46 77   44 61   2.00 0.17 
chitinase 3-like 4  Chi3l4   10308 13183   5603 9085   2169 10190   1.80 0.02 
                 
M2 Genes unchanged** upon induction of 
ischemia:             
Gene Symbol   
Baseline 
A 
Ischemia 
A   
Baseline 
B 
Ischemia 
B   
Baseline 
C 
Ischemia 
C   Fold ∆ 
p-
value 
Fc receptor, IgE, high affinity I, gamma 
polypeptide  Fcer1g   26927 19555   21773 21268   19015 21467   0.94 0.50 
macrophage galactose N-acetyl-
galactosamine specific lectin 2  Mgl2   1450 942   960 707   351 828   1.25 0.79 
mannose receptor, C type 1  Mrc1   168 213   203 72   415 231   0.73 0.39 
platelet-activating factor acetylhydrolase, 
isoform 1b Pafah1b1   2328 1877   1570 1782   1606 1701   1.00 0.86 
prosaposin  Psap   27140 22879   27001 28059   23643 25701   0.99 0.85 
transforming growth factor, beta 1  Tgfb1   1207 910   1138 789   134 885   2.69 0.92 
triggering receptor expressed on myeloid 
cells 2  Trem2   1146 946   700 766   1063 596   0.83 0.30 
arginase type II Vti1b   1509 1564   3011 4073   3548 3429   1.12 0.75 
              
M2 genes not expressed***:              
Gene Symbol   
Baseline 
A 
Ischemia 
A   
Baseline 
B 
Ischemia 
B   
Baseline 
C 
Ischemia 
C   Fold ∆ 
p-
value 
Fc receptor, IgE, low affinity II, alpha 
polypeptide Fcer2a   8 -3   -6 -2   8 -5   N/A N/A 
chemokine (C-C motif) ligand 22  Ccl22   -3 10   8 14   12 8   N/A N/A 
chemokine (C-C motif) ligand 17 Ccl17   10 5   3 6   19 -1   N/A N/A 
macrophage scavenger receptor 1 Msr1   -4 -1   -1 -2   7 3   N/A N/A 
macrophage scavenger receptor 2 Msr2   11 -2   17 5   27 -2   N/A N/A 
chemokine (C-C motif) ligand 2 Ccl2   43 43   14 11   21 12   N/A N/A 
chemokine (C-C) receptor 2 Ccr2   -6 -1   5 1   9 -2   N/A N/A 
interleukin 13 Il13   18 23   28 26   30 25   N/A N/A 
interleukin 1 receptor antagonist IL1RA   62 53   24 18   13 16   N/A N/A 
interleukin 10 (Il10) Il10   -8 -3   -3 -4   6 -1   N/A N/A 
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chemokine (C-C motif) ligand 17 Ccl17   10 5   3 6   19 -1   N/A N/A 
chemokine (C-C motif) ligand 22  Ccl22   -3 10   8 14   12 8   N/A N/A 
chemokine (C-C motif) ligand 24  Ccl24   12 16   5 10   16 3   N/A N/A 
resistin like alpha/Fizz1 Retnla   -6 -4   -1 -3   12 0   N/A N/A 
cadherin 1 Cdh1   6 6   1 6   12 10   N/A N/A 
folate receptor 2 (fetal) Folr2   -2 -4   -4 -6   9 9   N/A N/A 
CD163 antigen Cd163   -7 -2   2 -4   9 -2   N/A N/A 
*All genes which were expressed at levels greater than 40 relative expression units and which showed consistent      
induction or reduction across all three data sets are reported as 
"changed."           
**Genes which did not show consistent induction or reduction across all three data sets are reported as "unchanged."     
***Genes with a relative expression value <40 are reported as "not expressed."          
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4.1  SUMMARY 
 The studies outlined in this work lend insight into the mechanisms governing 
the regulation of angiogenesis by monocytes and also may have important 
implications for the design of cellular therapies for angiogenic disorders.  In this work 
we demonstrated that monocytes of the inflammatory subset are rapidly recruited to 
the ischemic tissue post-hindlimb ischemia.  A further proof of the importance of 
these cells in regulating post-ischemic angiogenesis was the accelerated 
revascularization observed when these cells were adoptively transferred into an 
ischemic recipient.  We also identified several factors that were produced upon 
adoptive transfer—VEGF, MCP-1, and MMP—each of which is a known player in 
the angiogenic repair.  Additionally, we identified apolipoprotein A1, a factor with a 
previously unknown role in angiogenesis, to be upregulated post-adoptive transfer.  
Interestingly, this protein must play a critical role in the mechanism by which 
adoptively transferred cells accelerate revascularization as ApoA1-/- monocytes did 
not mediate this effect.   
Having established that an adoptive transfer of monocytes does potently affect 
revascularization, we next sought to identify the ways in which the ischemic 
recipients’ own endogenous monocytes differed functionally from the non-ischemic 
donor cells used for the adoptive transfer.  We demonstrated that an adoptive transfer 
of monocytes obtained from an ischemic donor do not accelerate revascularization in 
the hindlimb ischemia model.  Our studies revealed that post-hindlimb ischemia there 
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is a marked increase in systemic levels of IL-6 and G-CSF and this is associated with 
increased STAT3 phosphorylation in bone marrow-resident monocytes.  In addition 
to the increased STAT3 activation observed, bone marrow resident monocytes also 
exhibited increased expression of M2 genes and a reduction in expression of M1 
genes.  In keeping with this finding, an adoptive transfer of SHIP-/- monocytes which 
are preferentially skewed to the M2 phenotype, does not accelerate revascularization 
in the hindlimb ischemia model.  This finding runs counter to tumor angiogenesis 
studies in which M2 macrophages are major contributors to angiogenesis and 
underscores the need to explore macrophage-regulated angiogenesis in a variety of 
ischemic settings.  Taken together our data identify a potent pro-angiogenic subset of 
monocytes (CX3CR1loGr-1+ inflammatory subset) and also reveal a profound defect 
in the ability of ischemia-conditioned monocytes to accelerate recovery from 
ischemia.  These findings can be exploited clinically by modifying current cell-based 
therapies for ischemic disorders such that they contain only this pro-angiogenic 
monocyte population (and not simply the unfractionated mononuclear cell 
compartment) and also potentially to obtain these cells from a matched, non-
autologous donor in order to avoid the negative impact of the ischemic-conditioning 
observed in our studies.  
 
4.2  APPLICATION TO OTHER ISCHEMIC MODELS 
A limitation of the studies described in this work is that only one model of 
ischemia and angiogenesis has been explored.  The mouse model for hindlimb 
ischemia we utilized generates an acute ischemia that is largely resolved after 
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approximately three weeks.  Therefore it is would be useful to compare the findings 
we obtained using this model and compare with other models of acute ischemia such 
as myocardial infarction or acute ischemic kidney injury to see if our findings 
regarding the efficacy of a monocyte adoptive transfer hold true in these settings as 
well.  While differences between these models will certainly exist, shared findings 
with regard to monocyte subsets involved and factors produced will corroborate and 
strengthen our conclusions from the hindlimb ischemia model.   
In the majority of patients with critical limb ischemia, atherosclerosis—which 
is a chronic, persistent inflammatory state—is the underlying cause.  In this way, our 
model for hindlimb ischemia does not accurately replicate this disease state.  It would 
be useful to compare our findings from the acute ischemia model utilized in our 
studies to a model for chronic ischemia.  For example, a model has been recently 
described in which the femoral artery excision surgery is performed in an ApoE-/- 
mouse; the combination of the femoral artery excision with the persistent 
inflammatory state in this mouse model better replicates chronic ischemia than 
femoral artery excision alone (Kang, 2008).  Results obtained from this model would 
provide insight into the ways in which the monocytic response differs between an 
acute versus a chronic ischemic insult. 
In addition to exploring the ways in which treatment with monocytes may be 
used as a pro-angiogenic therapy for ischemic disorders, it would also be useful to 
explore ways in which our findings may regulate pathologic neovascularization such 
as that observed during macular degeneration.  It would be useful to extend our 
findings to oxygen-induced retinopathy (OIR) and laser-induced choroidal 
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neovascularization (CNV) studies which model this disorder.   Such studies could 
focus on which macrophage subsets accumulate during the course of 
neovascularization.  It may also be useful to attempt to prevent neovascularization by 
neutralizing the pro-angiogenic factors we described in Chapter 2—for example 
treating these animals with the apolipoprotein A1 mimetic pepide in an effort to 
reduce angiogenesis.   
 
4.3  ROLE OF TYPE I INTERFERON 
In addition to revealing that several STAT3 targets were upregulated in 
ischemia-conditioned monocytes, microarray data revealed that several type I 
interferon-regulated genes were significantly downregulated (Table 3.2).  The role of 
type I interferons in the response to ischemia has not been extensively examined, 
however one study reported that IFNα/β, and not IFN-γ, is specifically induced in a 
mouse model of acute liver ischemia (Zhai, 2008).  The role that IFNα/β may play in 
regulating the development of bone marrow-resident monocytes is unclear.  One 
recent set of in vitro studies has indicated that bone marrow monocytes cultured 
under M2-polarizing conditions produce more endogenous IFN-β and express a far 
greater number of type I interferon target genes than do monocytes cultured under 
M1-polarizing conditions (Fleetwood, 2009).  If this finding hold true in vivo it may 
represent an important regulatory mechanism for the downstream polarization of bone 
marrow resident monoctyes.  Further studies are required in order to determine if 
tonic IFNα/β signaling does, in fact, occur in the bone marrow and what specific 
implications this regulation has on the downstream phenotype of these cells.   
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4.4  CLINICAL TRIAL USING MOBILIZING AGENTS TO RECRUIT 
MONOCYTES 
Our laboratory is currently enrolling patients with critical limb ischemia for a 
clinical trial in which they are treated for 10 days with G-CSF, a potent mobilizing 
agent, or placebo.  A total of 60 patients will be enrolled with 30 patients each in the 
treatment and placebo arms.  Eligibility criteria for patient enrollment includes a 
diagnosis of critical limb ischemia, defined as the presence of a non-healing ulcer or 
rest pain, secondary to peripheral arterial disease (PAD).  Patients in this study must 
not be candidates for a surgical revascularization procedure.  Additionally patients 
must have an absolute neutrophil count in the normal range and may not demonstrate 
an active infection or malignancy.  CD14/CD16 monocyte subsets as well as 
endothelial progenitor cells (EPCs) and lymphocytes will be measured by flow 
cytometry in peripheral blood obtained from patients prior to treatment as well as at 
and day 10 post-treatment.  The efficacy of this treatment will be assessed clinically 
by measuring ulcer size, ankle-brachial index, toe pressures, as well as a pain 
assessment.  The primary endpoint for these studies will be the rate of amputation at 
one year post-treatment.  The results of this study will demonstrate the specificity and 
magnitude of recruitment of the CD14-CD16+ and CD14+CD16- human monocyte 
subsets in response to treatment with G-CSF.  This study will also determine if 
mobilization of bone marrow-derived hematopoietic cells represents an efficacious 
treatment for critical limb ischemia.  If the results of this trial are disappointing, a 
modified protocol in which an alternative mobilizing agent, such as AMD-3100 may 
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yield better results based on the finding presented in this work that G-CSF, while it 
actively recruits monocytes to a site of ischemia, may also reduce their pro-
angiogenic potential.   
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